WO2024091037A1 - Biodegradable lipid nanoparticle drug delivery formulation targeting lungs - Google Patents
Biodegradable lipid nanoparticle drug delivery formulation targeting lungs Download PDFInfo
- Publication number
- WO2024091037A1 WO2024091037A1 PCT/KR2023/016792 KR2023016792W WO2024091037A1 WO 2024091037 A1 WO2024091037 A1 WO 2024091037A1 KR 2023016792 W KR2023016792 W KR 2023016792W WO 2024091037 A1 WO2024091037 A1 WO 2024091037A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipid
- peg
- lipid nanoparticles
- drug
- composition
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 151
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 98
- 210000004072 lung Anatomy 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 238000012377 drug delivery Methods 0.000 title description 4
- 238000009472 formulation Methods 0.000 title description 3
- 230000008685 targeting Effects 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 55
- 229940079593 drug Drugs 0.000 claims abstract description 49
- 125000000129 anionic group Chemical group 0.000 claims abstract description 23
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 claims description 29
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 22
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 18
- 208000019693 Lung disease Diseases 0.000 claims description 16
- -1 cationic lipid Chemical class 0.000 claims description 13
- 235000012000 cholesterol Nutrition 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 229920002477 rna polymer Polymers 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 5
- 102000053602 DNA Human genes 0.000 claims description 5
- 229940106189 ceramide Drugs 0.000 claims description 5
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 3
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 claims description 2
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 claims description 2
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 2
- SLQKYSPHBZMASJ-QKPORZECSA-N 24-methylene-cholest-8-en-3β-ol Chemical compound C([C@@]12C)C[C@H](O)C[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@H](C)CCC(=C)C(C)C)CC[C@H]21 SLQKYSPHBZMASJ-QKPORZECSA-N 0.000 claims description 2
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 claims description 2
- 206010001881 Alveolar proteinosis Diseases 0.000 claims description 2
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 claims description 2
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 claims description 2
- 206010006448 Bronchiolitis Diseases 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 claims description 2
- 108091027757 Deoxyribozyme Proteins 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000004852 Lung Injury Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 208000021063 Respiratory fume inhalation disease Diseases 0.000 claims description 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 2
- XYNPYHXGMWJBLV-VXPJTDKGSA-N Tomatidine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@@]11CC[C@H](C)CN1 XYNPYHXGMWJBLV-VXPJTDKGSA-N 0.000 claims description 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 2
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 claims description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 206010069351 acute lung injury Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 claims description 2
- JZVFJDZBLUFKCA-UTQQLQBSSA-N alpha-spinasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2C3=CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C JZVFJDZBLUFKCA-UTQQLQBSSA-N 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- SLQKYSPHBZMASJ-UHFFFAOYSA-N bastadin-1 Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(C)CCC(=C)C(C)C)CCC21 SLQKYSPHBZMASJ-UHFFFAOYSA-N 0.000 claims description 2
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 claims description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims description 2
- 235000004420 brassicasterol Nutrition 0.000 claims description 2
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 claims description 2
- 201000009267 bronchiectasis Diseases 0.000 claims description 2
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims description 2
- 235000000431 campesterol Nutrition 0.000 claims description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims description 2
- 230000009610 hypersensitivity Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 231100000515 lung injury Toxicity 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 210000003705 ribosome Anatomy 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- PWRIIDWSQYQFQD-UHFFFAOYSA-N sisunine Natural products CC1CCC2(NC1)OC3CC4C5CCC6CC(CCC6(C)C5CCC4(C)C3C2C)OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OC(CO)C(O)C(O)C9OC%10OC(CO)C(O)C(O)C%10O)C8O)C(O)C7O PWRIIDWSQYQFQD-UHFFFAOYSA-N 0.000 claims description 2
- 235000015500 sitosterol Nutrition 0.000 claims description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 2
- 229950005143 sitosterol Drugs 0.000 claims description 2
- 239000004055 small Interfering RNA Substances 0.000 claims description 2
- GHIZCSMTYWOBQA-BZSCQJQFSA-N spinasterol Natural products CC[C@H](C=C[C@@H](C)[C@@H]1CC[C@@]2(C)C3=CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C GHIZCSMTYWOBQA-BZSCQJQFSA-N 0.000 claims description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims description 2
- 229940032091 stigmasterol Drugs 0.000 claims description 2
- 235000016831 stigmasterol Nutrition 0.000 claims description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims description 2
- XYNPYHXGMWJBLV-OFMODGJOSA-N tomatidine Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@@H](C)[C@]6(O[C@H]5C4)NC[C@@H](C)CC6)CC3)CC2)CC1 XYNPYHXGMWJBLV-OFMODGJOSA-N 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 2
- 229940096998 ursolic acid Drugs 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 abstract description 13
- 238000001415 gene therapy Methods 0.000 abstract description 4
- 230000001404 mediated effect Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 21
- 238000001727 in vivo Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000010253 intravenous injection Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000002950 fibroblast Anatomy 0.000 description 10
- 238000005415 bioluminescence Methods 0.000 description 9
- 230000029918 bioluminescence Effects 0.000 description 9
- 238000012790 confirmation Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 8
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 8
- 210000005265 lung cell Anatomy 0.000 description 8
- 108010054624 red fluorescent protein Proteins 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000005538 encapsulation Methods 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000002479 lipoplex Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Definitions
- the present invention relates to a composition for transpulmonary delivery of a drug, comprising lipid nanoparticles containing ionizable lipids and cationic lipids of a specific structure, and its use in the prevention or treatment of lung diseases.
- Nucleic acids such as antisense RNA and mRNA are substances that can inhibit the expression of specific proteins in vivo, and are attracting attention as important tools in the treatment of cancer, genetic diseases, infectious diseases, and autoimmune diseases (Novina and Sharp, Nature, 430, 161-164, 2004). However, since nucleic acids are difficult to transfer directly into cells and are easily decomposed by enzymes in the blood, many studies are being conducted to overcome this problem.
- Drug Delivery System is a technology designed to efficiently deliver the required amount of drugs by reducing the side effects of drugs and maximizing their efficacy and effectiveness.
- conventional viral carriers have proven to be effective as drug carriers in gene therapy, but the use of viruses as a gene delivery system has been discouraged due to several drawbacks such as immunogenicity, limitations in the size of the injected DNA, and difficulties in mass production. It is being restricted.
- the method of transporting nucleic acids into cells is currently mixing them with positively charged lipids or polymers (named lipid-DNA conjugates (lipoplex) and polymer-DNA conjugates (polyplex), respectively). ) is mainly used (Hirko et al., Curr, Med, Chem., 10, 1185-1193, 2003; Merdan et al., Adv. Drug. Deliv.Rev., 54, 715-758, 2002; Spagnou et al. al., Biochemistry, 43, 13348-13386, 2004).
- lipid-DNA conjugates are widely used at the cellular level because they bind to nucleic acids and deliver nucleic acids well into cells, but when injected locally in vivo, they often cause inflammation in the body (Filonand and Phillips, Biochim. Biophys/Acta , 1329, 345-356, 1997), it has the disadvantage of accumulating in tissues such as the lung, liver, and spleen, which are the first passage organs during intravascular injection (Ren et al., Gene Therapy. 7, 764-768, 2000 ).
- the present inventors have made diligent efforts to develop a delivery vehicle that can effectively deliver anionic drugs such as nucleic acids specifically to lung tissue.
- a lipid nanoparticle formulation containing cationic lipids in addition to ionizable lipids with a specific structure has been developed into an excellent lung tissue.
- the present invention was completed by confirming that it had specific drug delivery efficacy.
- One object of the present invention is to provide a composition for transpulmonary delivery of a drug, comprising lipid nanoparticles containing ionizable lipids and cationic lipids having a specific structure.
- Another object of the present invention is to provide a pharmaceutical composition for preventing or treating lung diseases, comprising the lipid nanoparticles and anionic drugs.
- Lipid nanoparticles containing ionizable lipids and cationic lipids of the present invention are specifically delivered to lung tissue, have excellent biocompatibility, and can deliver anionic drugs with high efficiency, thereby enabling related technologies such as lipid nanoparticle-mediated gene therapy. It can be useful in this field.
- Figure 1 shows the results of hEPO levels analyzed by intravenous injection into mice and blood collection to confirm in vivo delivery of hEPO mRNA-encapsulated 244-cis lipid nanoparticles.
- Figure 2 shows the results of confirming the EPO protein level and MCP-1 level in the blood after intravenous injection into mice to confirm the in vivo delivery efficacy of hEPO mRNA-encapsulated 244-cis lipid nanoparticles.
- Figure 3 shows the results of confirming the level of MCP-1 secretion depending on whether hEPO mRNA-encapsulated 244-cis lipid nanoparticles contain DOTAP.
- Figure 4 shows the results of confirming the bioluminescence of 244-cis lipid nanoparticles encapsulated with fLuc mRNA and containing DOPE.
- Figure 5 shows the results of bioluminescence after intravenous injection into mice to confirm the in vivo delivery efficacy of 244-cis lipid nanoparticles encapsulated with fLuc mRNA and containing 10 mol% of DOTAP.
- Figure 6 shows the results of bioluminescence after intravenous injection into mice to confirm the in vivo delivery efficacy of 244-cis lipid nanoparticles encapsulated with fLuc mRNA and containing 20 mol% DOTAP.
- Figure 7 shows the results of bioluminescence after intravenous injection into mice to confirm the in vivo delivery efficacy of 244-cis lipid nanoparticles encapsulated with fLuc mRNA and containing 40 mol% of DOTAP.
- Figure 8 shows the results of bioluminescence after intravenous injection into mice to confirm the in vivo delivery efficacy of 244-cis lipid nanoparticles encapsulated with fLuc mRNA and containing 60 mol% of DOTAP.
- Figure 9 shows the results of comparing the distribution of luminescence in each organ after intravenous injection into mice to confirm the in vivo delivery efficacy according to the DOTAP-containing ratio of lipid nanoparticles encapsulated with fLuc mRNA.
- Figure 10 shows the results of bioluminescence after intravenous injection into mice to confirm the in vivo delivery efficacy of 244-cis lipid nanoparticles encapsulated with fLuc mRNA and containing 20 mol% phosphatidylcholine.
- Figure 11 shows the results of bioluminescence after intravenous injection into mice to confirm the in vivo delivery efficacy of 244-cis lipid nanoparticles encapsulated with fLuc mRNA and containing 40 mol% phosphatidylcholine.
- Figure 12 shows the results of comparing fluorescence expression in each lung cell after intravenous injection of Cre mRNA-encapsulated 244-cis lipid nanoparticles into LSL-tdTomato mice.
- Figure 13 shows the results of comparing the fluorescence expression of each lung cell after intravenous injection of Cre mRNA-encapsulated 244-cis lipid nanoparticles into LSL-tdTomato mice with lung fibrosis.
- Figure 14 shows the results of confirming fluorescence expression in Sca-1 + cells of fibroblasts after intravenous injection of Cre mRNA-encapsulated 244-cis lipid nanoparticles into LSL-tdTomato mice with lung fibrosis.
- LNPs lipid nanoparticles
- ionizable lipids ionizable lipids
- cationic lipids represented by the following formula (1): , a composition for transpulmonary delivery of drugs.
- ionizable lipid refers to an amine-containing lipid that can be easily protonated, and is also called a lipid analog (lipidoid). Since the charge state of the ionizable lipid can change depending on the surrounding pH, it plays a role in ensuring that the drug is encapsulated within the lipid nanoparticle with high efficiency through electrostatic interaction with the anionic drug, and the structure of the lipid nanoparticle contributes to forming
- One feature of the lipid nanoparticles of the present invention is that they contain an ionizable lipid of the above formula (1).
- the ionizable lipid of Formula 1 is a substance having a head group having a plurality of tertiary amines, an ester functional group, and a chain tail containing a carbon double bond, and is named “244-cis” in the present invention.
- the present inventors found that ionizable lipids with 244-cis or similar structures can be used as a component of lipid nanoparticles, and that the lipid nanoparticles are excellent for delivering anionic drugs such as mRNA. It has been reported that it is effective.
- the present inventors found that the target tissue of the ionizable lipid surprisingly varies depending on the type of helper lipid with which it is combined, and in particular, when lipid nanoparticles are manufactured using cationic lipid as a helper lipid, it is targeted specifically at the lungs. Delivery was confirmed. In addition, it was confirmed that the lipid nanoparticles of the present invention stably delivered mRNA with little immunogenicity and were expressed at a high level at the target site.
- the present invention can be applied not only to the ionizable lipid represented by Formula 1, that is, 244-cis, but also to the ionizable lipid having a similar structure.
- ionizable lipid of Formula 1 that is, 244-cis
- Those skilled in the art can fully expect that beyond the scope of the ionizable lipid of Formula 1, for example, other ionizable lipids with similar structures described in WO2023/136689 can show the same effects as those confirmed in the present invention. Therefore, all ionizable lipids with structures similar to 244-cis can also be included within the scope of the present invention as equivalents.
- the ionizable lipid of the present invention may be a compound represented by the following formula (2).
- Y is -O- or -NH-
- n 1 to 2
- n is an integer from 3 to 7
- x is an integer from 1 to 3
- l is an integer from 3 to 4, and
- p is an integer from 0 to 2.
- the compound represented by Formula 2 may be selected from the group consisting of compounds shown in Table 1 below.
- alkyl refers to a straight-chain or branched-chain acyclic saturated hydrocarbon, unless otherwise specified.
- C 1-6 alkyl may mean alkyl containing 1 to 6 carbon atoms.
- lipid nanoparticles of the present invention contain cationic lipids.
- the cationic lipid corresponds to a helper lipid in lipid nanoparticles and, together with the ionizable lipid of the present invention, plays a role in delivering anionic drugs specifically to the lungs.
- helper lipid serves to surround and protect the core formed by the interaction of ionizable lipids and drugs within lipid nanoparticles, and binds to the phospholipid bilayer of the target cell to protect the drug. When delivered intracellularly, it facilitates cell membrane passage and endosomal escape.
- the “cationic lipid” may be DOTAP (1,2-dioleoyl-3-trimethylammonium propane) or phosphatidylcholine, but is not limited thereto.
- phosphatidylcholine refers to a type of phospholipid and a compound containing choline as a head group. It is widely present in animals, plants, yeast, and molds, and is also called lecithin. It is a membrane phospholipid of mammals and is mainly contained in brain water, nerves, blood cells, and egg yolk. In plants, it is contained in soybeans, sunflower seeds, and wheat germ. In general, glycerol often has a saturated fatty acid bound to the 1st position and an unsaturated fatty acid bound to the 2nd position.
- phosphatidylcholine may be a mixture of phosphatidylcholine of various structures, may be isolated from natural products (e.g., egg yolk, soybeans, etc.), or may be chemically synthesized.
- the lipid nanoparticles of the present invention may contain DOTAP in an amount of 10 mol% to 70 mol% based on the entire lipid nanoparticle, for example, 15 mol% to 70 mol%, 20 mol%. It may be from 70 mol%, 15 mol% to 65 mol%, 20 mol% to 65 mol%, 20 mol% to 60 mol%, or 20 mol% to 50 mol%, but is not limited thereto.
- the lipid nanoparticles of the present invention contain 10 mol% to 50 mol%, 15 mol% to 45 mol%, or 20 mol% to 60 mol% of phosphatidylcholine based on the total lipid nanoparticles.
- 10 mol% to 50 mol% 15 mol% to 45 mol%
- 20 mol% to 60 mol% of phosphatidylcholine based on the total lipid nanoparticles.
- lipid nanoparticles when lipid nanoparticles are prepared using 244-cis ionizable lipids, they are generally mostly delivered to the liver ( Figure 4), but when they contain cationic lipids such as DOTAP or phosphatidylcholine, It was confirmed that mRNA was expressed through lung-specific delivery ( Figures 5 to 11). Therefore, lipid nanoparticles containing ionizable lipids and cationic lipids represented by Formula 1 (or Formula 2) of the present invention are specifically delivered to lung tissue, and thus deliver anionic drugs specifically to the lungs with high efficiency. It can be passed on.
- Formula 1 or Formula 2
- the lipid nanoparticles of the present invention may further include structural lipids or PEG-lipids.
- the structural lipid maintains the particle shape within the lipid nanoparticle and is dispersed on the core and surface of the nanoparticle to improve the stability of the nanoparticle.
- the structural lipid is, for example, cholesterol, cholesterol, spinasterol, fecosterol, sitosterol, ergosterol, ergostenol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol or these. It may be a mixture of, but is not limited thereto.
- the PEG-lipid refers to a conjugated form of lipid and PEG, and refers to a lipid to which polyethylene glycol polymer, a hydrophilic polymer, is bound.
- the PEG-lipid within lipid nanoparticles contributes to particle stability in serum and plays a role in preventing aggregation between nanoparticles.
- PEG-lipids protect nucleic acids from degrading enzymes, enhance the stability of nucleic acids in the body, and can increase the half-life of drugs encapsulated in nanoparticles.
- the PEG-lipid may be, for example, PEG-ceramide, PEG-DMG, PEG-c-DOMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, PEG-DSPE or mixtures thereof, specifically C16-PEG2000 ceramide. However, it is not limited to this.
- the molar ratio of ionizable lipid: DOTAP: structural lipid: PEG-lipid is 10 to 40. : 5 to 80 : 5 to 80 : 1 to 5. More specifically, the molar ratio may be 20 to 30: 10 to 70: 10 to 70: 1 to 5, and more specifically, 20 to 30: 15 to 70: 15 to 70: 1 to 3. Not limited.
- the molar ratio of ionizable lipid: phosphatidylcholine: structural lipid: PEG-lipid is 10 to 10. It may be 40:5 to 80:5 to 80:1 to 5. More specifically, the molar ratio may be 20 to 30:10 to 50:30 to 60:1 to 5, and more specifically, 20 to 30:20 to 40:30 to 60:1 to 3. Not limited.
- the lipid nanoparticles of the present invention exhibit a positive charge under acidic pH conditions, they can easily form a complex with the drug through electrostatic interaction with therapeutic agents such as nucleic acids and drugs that exhibit a negative charge, allowing the encapsulation of anionic drugs with high efficiency. It can be used as an intracellular or in vivo drug delivery composition. Therefore, the lipid nanoparticles of the present invention can be useful for the delivery of not only nucleic acids but also all types of drugs with anionic properties. That is, the lipid nanoparticles of the present invention can ultimately be manufactured in a form (encapsulated form) that additionally contains an anionic drug, and the encapsulated anionic drug can be specifically delivered to the lungs.
- the term "encapsulation” refers to encapsulating the delivery material to surround it and efficiently incorporate it into the body
- the drug encapsulation efficiency refers to the lipid content relative to the total drug content used in manufacturing. It refers to the content of drug encapsulated in nanoparticles.
- the anionic drug may be a nucleic acid, low molecular weight compound, peptide, protein, protein-nucleic acid structure, or anionic biopolymer-drug conjugate, but may be stably and efficiently delivered by forming lipid nanoparticles together with the ionizable lipid of the present invention. It is not limited to this as long as possible.
- the nucleic acids include small interfering ribonucleic acid (siRNA), ribosomal ribonucleic acid (rRNA), deoxyribonucleic acid (DNA), complementary deoxyribonucleic acid (cDNA), aptamer, messenger ribonucleic acid (mRNA), and transport ribonucleic acid. It may be (tRNA), sgRNA, antisense oligonucleotide, shRNA, miRNA, ribozyme, PNA, and DNAzyme, or a mixture thereof, but is not limited thereto.
- siRNA small interfering ribonucleic acid
- rRNA ribosomal ribonucleic acid
- DNA deoxyribonucleic acid
- cDNA complementary deoxyribonucleic acid
- aptamer messenger ribonucleic acid
- mRNA messenger ribonucleic acid
- mRNA messenger ribonucleic acid
- transport ribonucleic acid It
- the weight ratio of total lipid/nucleic acid in the lipid nanoparticles may be 1 to 30, specifically 5 to 27, and more specifically 10 to 23, but is not limited thereto.
- Another aspect of the present invention is a pharmaceutical composition for preventing or treating lung disease, comprising lipid nanoparticles containing the ionizable lipid and cationic lipid of Formula 1 above, and an anionic drug as an active ingredient.
- Another aspect of the present invention is a method of treating lung disease, comprising administering the composition to an individual in need thereof.
- Another aspect of the present invention is a pharmaceutical composition for use in the prevention or treatment of lung disease, or use of the composition for the prevention or treatment of lung disease.
- Lipid nanoparticles and anionic drugs are as described above.
- the lipid nanoparticles of the present invention form a stable complex with anionic drugs such as nucleic acids and exhibit low cytotoxicity and effective cell absorption, so they are effective in delivering anionic drugs.
- anionic drugs such as nucleic acids
- the lipid nanoparticles can be specifically delivered to the lungs when administered, they can be useful in preventing or treating lung diseases.
- the lipid nanoparticles of the present invention can specifically deliver drugs by targeting the lungs, and for the purpose of the present invention, prevent or treat various lung diseases depending on the type of anionic drug, type of nucleic acid, and nucleic acid sequence used. Effects can be expected. That is, in the present invention, the type of lung disease is not limited. Therefore, the lung diseases include, for example, emphysema, asthma, pneumonia, tuberculosis, pulmonary hypertension, lung cancer, neonatal bronchopulmonary dysplasia, chronic obstructive pulmonary disease, acute bronchitis, chronic bronchitis, bronchiolitis, bronchiectasis, hypersensitivity, lung parenchyma.
- the lung diseases include, for example, emphysema, asthma, pneumonia, tuberculosis, pulmonary hypertension, lung cancer, neonatal bronchopulmonary dysplasia, chronic obstructive pulmonary disease, acute bronchitis, chronic bronchit
- the term “treatment” refers to intervention to alter the natural processes of an individual or cell with a disease, which may be performed during the progression of the pathology or to prevent it.
- the desired therapeutic effects include preventing the occurrence or recurrence of the disease, alleviating symptoms, reducing all direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, and alleviating the disease state. Or it includes temporary relief, remission, or improvement of prognosis.
- the present invention includes all actions to improve the course of lung-related diseases by administering a composition containing lipid nanoparticles containing ionizable lipids and cationic lipids and anionic drugs as active ingredients.
- prevention refers to all actions that suppress or delay the onset of a disease by administering the lipid nanoparticles.
- the lipid nanoparticles of the present invention are used for treatment or prevention purposes, they are administered to an individual in a therapeutically effective amount.
- therapeutically effective amount refers to an effective amount of anionic drug-containing lipid nanoparticles.
- therapeutically effective amount means an amount sufficient to treat the disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is determined by the type and severity of the individual, age, gender, type of disease, It can be determined based on factors including the activity of the drug, sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, drugs used simultaneously, and other factors well known in the medical field.
- the pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with commercially available therapeutic agents. And it can be administered single or multiple times.
- the administered dose of the pharmaceutical composition of the present invention may be determined by an expert depending on various factors such as the patient's condition, age, gender, and complications. Since the active ingredient of the composition of the present invention has excellent safety, it can be used beyond the determined administration dose.
- composition containing the lipid nanoparticles may be administered orally, intramuscularly, intravenously, arterially, subcutaneously, intraperitoneally, pulmonaryly, and intranasally, and may specifically be administered intravenously, but is not limited thereto.
- composition of the present invention may further include one or more pharmaceutically acceptable carriers for administration.
- Pharmaceutically acceptable carriers can be saline solution, sterile water, Ringer's solution, buffered saline solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and a mixture of one or more of these ingredients, and if necessary, antioxidants, buffer solutions, Other common additives such as bacteriostatic agents can be added.
- Example 1 Preparation of lipid nanoparticles for transpulmonary delivery
- 244-cis (see WO2023/136689) was prepared as an ionizable lipid and synthesized according to Scheme 1 below.
- lipid nanoparticles containing 244-cis were named '244-cis lipid nanoparticles'.
- SM-102 or MC3 was used as a control.
- Ionizable lipids cationic lipids
- DOTAP 1,2-dioleoyl-3-trimethylammonium propane
- DOPE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine
- EPC egg phosphatidylcholine (Avanti, 890704P)
- cholesterol Cholesterol powder, BioReagent, for cell culture, ⁇ 99%, Sigma, Korea
- C16-PEG2000 ceramide (Avanti, USA) were dissolved in ethanol at a molar ratio of 26.5:10 to 60:12 to 62:1.5 (Table 2). I ordered it.
- ingredient Content mol% ionizable lipids 26.5 26.5 26.5 26.5 cationic lipids 10 20 40 60 cholesterol 62 52 32 12 PEG-lipid 1.5 1.5 1.5 1.5 1.5
- Ionizable lipids, cholesterol, cationic lipids, and PEG-ceramide conjugates were dissolved in ethanol and nucleic acids (mRNA) were dissolved in aqueous phase (sodium acetate or sodium citrate) at a volume ratio of 1:3 at a flow rate of 12 ml/min.
- mRNA nucleic acids
- Lipid nanoparticles were prepared by mixing using a microfluidic mixing device (Benchtop Nanoassemblr; PNI, Canada). The weight ratio of mRNA:ionizable lipid was 1:20.
- hEPO mRNA (SEQ ID NO: 1) was encapsulated, and lipid nanoparticles containing 244-cis, DOPE (20 mol%), cholesterol, and PEG-lipid were administered intravenously to 7-week-old Balb/c mice at a dose of 0.1 mg/kg based on mRNA. Injected. Blood was collected after 3, 6, 9, 24, and 48 hours, and hEPO protein expression was confirmed using ELISA (R&D systems, USA) ( Figure 1).
- lipid nanoparticles containing 244-cis effectively delivered and expressed nucleic acids in vivo, and hEPO was detected at a significant level in the blood.
- Lipid nanoparticles containing 244-cis showed a significantly higher level than the control MC3 LNP, and showed a level equivalent to that of SM-102 LNP.
- the lipid nanoparticles of Experimental Example 1-1 were injected intravenously into 7-week-old Balb/c mice at a dose of 0.5 mg/kg based on mRNA, and blood was collected 3 hours later. MCP-1 protein expression was confirmed using ELISA (Invitrogen, USA) ( Figure 2).
- Lipid nanoparticles in which DOPE was replaced with DOTAP in the 244-cis lipid nanoparticles of Experimental Example 1-1 above were injected intravenously into 7-week-old Balb/c mice at a dose of 0.5 mg/kg based on mRNA, and blood was collected 6 hours later. did. MCP-1 protein expression was confirmed using ELISA (Invitrogen, USA) ( Figure 3).
- fLuciferase mRNA (SEQ ID NO: 2) was encapsulated and lipid nanoparticles containing 244-cis, DOTAP, cholesterol, and PEG-lipid were prepared according to the contents in Table 2, and administered to 7-week-old C57BL/6 at a dose of 0.2 mg/kg based on mRNA. It was injected intravenously into mice. Six hours later, 0.25 mg/kg of luciferin was administered intraperitoneally, and bioluminescence was confirmed through ex vivo organ images using IVIS (PerkinElmer, USA) equipment (FIGS. 4 to 8). As a control, DOPE-containing lipid nanoparticles were used.
- Lipid nanoparticles containing 244-cis and phosphatidylcholine (EPC) were prepared according to the contents in Table 2, and 0.1 mg/kg of mRNA was injected intravenously into 7-week-old C57BL/6 mice. Six hours later, 0.25 mg/kg of luciferin was administered intraperitoneally, and bioluminescence was confirmed through ex vivo organ images using IVIS (PerkinElmer, USA) equipment (FIGS. 10 and 11).
- 244-cis lipid nanoparticles containing phosphatidylcholine showed high lung-specific luminescence intensity.
- LSL-tdTomato mice (The Jackson Laboratory #: 007914), which express Tomato protein using Cre protein, were used.
- Cre mRNA SEQ ID NO: 3
- lipid nanoparticles containing 244-cis, DOTAP (20 mol%), cholesterol, and PEG-lipid were administered to 7-week-old LSL-tdTomato mice at a dose of 0.3 mg/kg based on mRNA. It was administered intravenously twice at daily intervals.
- lung tissue cells were isolated and tdTomato fluorescence expression in each lung cell (endothelial cells, fibroblasts, epithelial cells, immune cells) was confirmed using flow cytometry (LSRFortessa, BD) ( Figure 12).
- APC anti-mouse CD31 antibody BioLegend; 102409) for staining endothelial cells
- FITC anti-mouse CD45.2 antibody BioLegend; 109805
- PE/Cyanine7 anti-mouse CD326 antibody BioLegend; 109805
- lung tissue cells were isolated and tdTomato fluorescence expression was confirmed in each lung cell (endothelial cells, fibroblasts, epithelial cells, immune cells) using flow cytometry (LSRFortessa, BD) ( Figures 13 and 14 ).
- the lipid nanoparticles of the present invention showed overwhelmingly higher expression than the control MC3 LNP in all types of lung cells.
- endothelial cells showed over 80% tdTomato expression
- epithelial cells, immune cells, and fibroblasts also showed tdTomato expression at a level of about 30% (Figure 13).
- tdTomato expression was shown by more than 40%, especially in Sca-1 + fibroblasts ( Figure 14).
- the 244-cis LNP of the present invention can deliver and express mRNA specifically to the lung compared to the MC3 LNP, and can specifically deliver mRNA to fibroblasts in a lung fibrosis model.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a composition for transpulmonary delivery of drugs and a use thereof. Lipid nanoparticles containing ionizable lipids and cationic lipids of the present invention are specifically delivered to lung tissue and specific cells thereof, have excellent biocompatibility, and can deliver anionic drugs with high efficiency, and thus can be useful in relevant technical fields such as lipid nanoparticle-mediated gene therapy.
Description
본 발명은 특정 구조의 이온화 가능 지질 및 양이온성 지질을 포함하는 지질나노입자를 포함하는, 약물의 경폐 전달용 조성물 및 이의 폐 질환의 예방 또는 치료 용도에 관한 것이다.The present invention relates to a composition for transpulmonary delivery of a drug, comprising lipid nanoparticles containing ionizable lipids and cationic lipids of a specific structure, and its use in the prevention or treatment of lung diseases.
Antisense RNA, mRNA 등의 핵산은 생체 내에서 특정 단백질의 발현을 억제할 수 있는 물질로, 암, 유전병, 감염질병, 자가면역 질환 등의 치료에 중요한 도구로 각광받고 있다 (Novina and Sharp, Nature, 430, 161-164, 2004). 그러나 핵산은 세포 내로 직접 전달이 어렵고, 혈액 내에서 효소에 의해 쉽게 분해되므로 이를 극복하기 위한 연구들이 많이 진행되고 있다.Nucleic acids such as antisense RNA and mRNA are substances that can inhibit the expression of specific proteins in vivo, and are attracting attention as important tools in the treatment of cancer, genetic diseases, infectious diseases, and autoimmune diseases (Novina and Sharp, Nature, 430, 161-164, 2004). However, since nucleic acids are difficult to transfer directly into cells and are easily decomposed by enzymes in the blood, many studies are being conducted to overcome this problem.
약물전달시스템 (DDS; Drug Delivery System)은 약물의 부작용을 줄이고 효능 및 효과를 극대화시켜 필요한 양의 약물을 효율적으로 전달할 수 있도록 설계한 기술이다. 특히, 유전자 치료에 있어서 약물 전달체로는 종래 바이러스 전달체가 효과적임이 입증되었으나, 면역원성 (immunogenicity), 주입된 DNA 크기의 한계 및 대량생산의 어려움과 같은 여러 결점으로 인해 유전자 전달시스템으로서 바이러스의 이용이 제한되고 있다.Drug Delivery System (DDS) is a technology designed to efficiently deliver the required amount of drugs by reducing the side effects of drugs and maximizing their efficacy and effectiveness. In particular, conventional viral carriers have proven to be effective as drug carriers in gene therapy, but the use of viruses as a gene delivery system has been discouraged due to several drawbacks such as immunogenicity, limitations in the size of the injected DNA, and difficulties in mass production. It is being restricted.
이에, 바이러스성 시스템의 대체 수단으로 핵산을 세포 내로 운반하는 방법으로는 현재까지 양전하 지질 또는 중합체와 섞어 운반하는 방법 (각각, 지질-DNA 접합체 (lipoplex) 및 폴리머-DNA 접합체 (polyplex)라 명명됨)이 주로 사용되고 있다 (Hirko et al., Curr, Med, Chem., 10, 1185-1193, 2003; Merdan et al., Adv. Drug. Deliv.Rev., 54, 715-758, 2002; Spagnou et al., Biochemistry, 43, 13348-13386, 2004). 특히, 지질-DNA 접합체는 핵산과 결합하여 세포 내로 핵산을 잘 전달시켜 세포수준에서 많이 사용되고 있으나, 생체 내에서는 국부적으로 주사 시 많은 경우 체내에서 염증을 유발시키며 (Filonand and Phillips, Biochim. Biophys/Acta, 1329, 345-356, 1997), 혈관 내 주사 시 주로 1차 통과기관들인 폐, 간, 비장 등과 같은 조직에 축적되는 단점이 있다 (Ren et al., Gene Therapy. 7, 764-768, 2000).Accordingly, as an alternative to the viral system, the method of transporting nucleic acids into cells is currently mixing them with positively charged lipids or polymers (named lipid-DNA conjugates (lipoplex) and polymer-DNA conjugates (polyplex), respectively). ) is mainly used (Hirko et al., Curr, Med, Chem., 10, 1185-1193, 2003; Merdan et al., Adv. Drug. Deliv.Rev., 54, 715-758, 2002; Spagnou et al. al., Biochemistry, 43, 13348-13386, 2004). In particular, lipid-DNA conjugates are widely used at the cellular level because they bind to nucleic acids and deliver nucleic acids well into cells, but when injected locally in vivo, they often cause inflammation in the body (Filonand and Phillips, Biochim. Biophys/Acta , 1329, 345-356, 1997), it has the disadvantage of accumulating in tissues such as the lung, liver, and spleen, which are the first passage organs during intravascular injection (Ren et al., Gene Therapy. 7, 764-768, 2000 ).
본 발명자들은 폐 조직 특이적으로 핵산 등의 음이온성 약물을 효과적으로 전달할 수 있는 전달체를 개발하고자 예의 노력한 결과, 특정한 구조를 갖는 이온화 가능 지질에 추가로 양이온성 지질을 포함하는 지질나노입자 제형이 우수한 폐 특이적 약물 전달 효능을 가짐을 확인함으로써 본 발명을 완성하였다.The present inventors have made diligent efforts to develop a delivery vehicle that can effectively deliver anionic drugs such as nucleic acids specifically to lung tissue. As a result, a lipid nanoparticle formulation containing cationic lipids in addition to ionizable lipids with a specific structure has been developed into an excellent lung tissue. The present invention was completed by confirming that it had specific drug delivery efficacy.
본 발명의 하나의 목적은, 특정 구조를 갖는 이온화 가능 지질 및 양이온성 지질을 포함하는 지질나노입자를 포함하는, 약물의 경폐 전달용 조성물을 제공하는 것이다.One object of the present invention is to provide a composition for transpulmonary delivery of a drug, comprising lipid nanoparticles containing ionizable lipids and cationic lipids having a specific structure.
본 발명의 다른 하나의 목적은, 상기 지질나노입자 및 음이온성 약물을 포함하는, 폐 질환의 예방 또는 치료용 약학적 조성물을 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for preventing or treating lung diseases, comprising the lipid nanoparticles and anionic drugs.
본 발명의 이온화 가능 지질 및 양이온성 지질을 포함하는 지질나노입자는 폐 조직에 특이적으로 전달되고 생체 친화도가 우수하며, 고효율로 음이온성 약물을 전달할 수 있어 지질나노입자 매개 유전자 치료 등 관련 기술분야에 유용하게 활용될 수 있다.Lipid nanoparticles containing ionizable lipids and cationic lipids of the present invention are specifically delivered to lung tissue, have excellent biocompatibility, and can deliver anionic drugs with high efficiency, thereby enabling related technologies such as lipid nanoparticle-mediated gene therapy. It can be useful in this field.
도 1은 hEPO mRNA 봉입 244-cis 지질나노입자의 생체 내 전달을 확인하기 위하여 마우스에 정맥주사한 후 채혈하여 hEPO 수준을 분석한 결과이다.Figure 1 shows the results of hEPO levels analyzed by intravenous injection into mice and blood collection to confirm in vivo delivery of hEPO mRNA-encapsulated 244-cis lipid nanoparticles.
도 2는 hEPO mRNA 봉입 244-cis 지질나노입자의 생체 내 전달효능을 확인하기 위하여 마우스에 정맥주사한 후 혈액내 EPO 단백질 수준 및 MCP-1 수치를 확인한 결과이다.Figure 2 shows the results of confirming the EPO protein level and MCP-1 level in the blood after intravenous injection into mice to confirm the in vivo delivery efficacy of hEPO mRNA-encapsulated 244-cis lipid nanoparticles.
도 3은 hEPO mRNA 봉입 244-cis 지질나노입자의 DOTAP 함유 여부에 따른 MCP-1 분비 정도를 확인한 결과이다.Figure 3 shows the results of confirming the level of MCP-1 secretion depending on whether hEPO mRNA-encapsulated 244-cis lipid nanoparticles contain DOTAP.
도 4는 fLuc mRNA가 봉입되고 DOPE를 포함하는 244-cis 지질나노입자의 생체발광을 확인한 결과이다.Figure 4 shows the results of confirming the bioluminescence of 244-cis lipid nanoparticles encapsulated with fLuc mRNA and containing DOPE.
도 5는 fLuc mRNA가 봉입되고 10 mol%의 DOTAP을 포함하는 244-cis 지질나노입자의 생체 내 전달효능을 확인하기 위하여 마우스에 정맥주사한 후 생체발광을 확인한 결과이다.Figure 5 shows the results of bioluminescence after intravenous injection into mice to confirm the in vivo delivery efficacy of 244-cis lipid nanoparticles encapsulated with fLuc mRNA and containing 10 mol% of DOTAP.
도 6은 fLuc mRNA가 봉입되고 20 mol%의 DOTAP을 포함하는 244-cis 지질나노입자의 생체 내 전달효능을 확인하기 위하여 마우스에 정맥주사한 후 생체발광을 확인한 결과이다.Figure 6 shows the results of bioluminescence after intravenous injection into mice to confirm the in vivo delivery efficacy of 244-cis lipid nanoparticles encapsulated with fLuc mRNA and containing 20 mol% DOTAP.
도 7은 fLuc mRNA가 봉입되고 40 mol%의 DOTAP을 포함하는 244-cis 지질나노입자의 생체 내 전달효능을 확인하기 위하여 마우스에 정맥주사한 후 생체발광을 확인한 결과이다.Figure 7 shows the results of bioluminescence after intravenous injection into mice to confirm the in vivo delivery efficacy of 244-cis lipid nanoparticles encapsulated with fLuc mRNA and containing 40 mol% of DOTAP.
도 8은 fLuc mRNA가 봉입되고 60 mol%의 DOTAP을 포함하는 244-cis 지질나노입자의 생체 내 전달효능을 확인하기 위하여 마우스에 정맥주사한 후 생체발광을 확인한 결과이다.Figure 8 shows the results of bioluminescence after intravenous injection into mice to confirm the in vivo delivery efficacy of 244-cis lipid nanoparticles encapsulated with fLuc mRNA and containing 60 mol% of DOTAP.
도 9는 fLuc mRNA가 봉입된 지질나노입자의 DOTAP을 포함하는 비율에 따른 생체 내 전달효능을 확인하기 위하여 마우스에 정맥주사한 후 각 장기 별 발광 분포를 확인하여 비교한 결과이다.Figure 9 shows the results of comparing the distribution of luminescence in each organ after intravenous injection into mice to confirm the in vivo delivery efficacy according to the DOTAP-containing ratio of lipid nanoparticles encapsulated with fLuc mRNA.
도 10은 fLuc mRNA가 봉입되고 20 mol%의 포스파티딜콜린을 포함하는 244-cis 지질나노입자의 생체 내 전달효능을 확인하기 위하여 마우스에 정맥주사한 후 생체발광을 확인한 결과이다.Figure 10 shows the results of bioluminescence after intravenous injection into mice to confirm the in vivo delivery efficacy of 244-cis lipid nanoparticles encapsulated with fLuc mRNA and containing 20 mol% phosphatidylcholine.
도 11은 fLuc mRNA가 봉입되고 40 mol%의 포스파티딜콜린을 포함하는 244-cis 지질나노입자의 생체 내 전달효능을 확인하기 위하여 마우스에 정맥주사한 후 생체발광을 확인한 결과이다.Figure 11 shows the results of bioluminescence after intravenous injection into mice to confirm the in vivo delivery efficacy of 244-cis lipid nanoparticles encapsulated with fLuc mRNA and containing 40 mol% phosphatidylcholine.
도 12는 Cre mRNA 봉입 244-cis 지질나노입자를 LSL-tdTomato 마우스에 정맥주사 후 폐 세포별 형광발현을 비교한 결과이다.Figure 12 shows the results of comparing fluorescence expression in each lung cell after intravenous injection of Cre mRNA-encapsulated 244-cis lipid nanoparticles into LSL-tdTomato mice.
도 13은 Cre mRNA 봉입 244-cis 지질나노입자를 폐 섬유화가 일어난 LSL-tdTomato 마우스에 정맥주사 후 폐 세포별 형광발현을 비교한 결과이다.Figure 13 shows the results of comparing the fluorescence expression of each lung cell after intravenous injection of Cre mRNA-encapsulated 244-cis lipid nanoparticles into LSL-tdTomato mice with lung fibrosis.
도 14는 Cre mRNA 봉입 244-cis 지질나노입자를 폐 섬유화가 일어난 LSL-tdTomato 마우스에 정맥주사 후 섬유아세포의 Sca-1+ 세포에서의 형광발현을 확인한 결과이다.Figure 14 shows the results of confirming fluorescence expression in Sca-1 + cells of fibroblasts after intravenous injection of Cre mRNA-encapsulated 244-cis lipid nanoparticles into LSL-tdTomato mice with lung fibrosis.
이를 구체적으로 설명하면 다음과 같다. 한편, 본 발명에서 개시된 각각의 설명 및 실시형태는 각각의 다른 설명 및 실시형태에도 적용될 수 있다. 즉, 본 발명에서 개시된 다양한 요소들의 모든 조합이 본 발명의 범주에 속한다. 또한, 하기 기술된 구체적인 서술에 의하여 본 발명의 범주가 제한된다고 볼 수 없다.This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in the present invention can also be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in the present invention fall within the scope of the present invention. Additionally, the scope of the present invention cannot be considered to be limited by the specific description described below.
상기 목적을 달성하기 위한 본 발명의 하나의 양태는, 하기 화학식 1로 표시되는 이온화 가능 지질 (ionizable lipid) 및 양이온성 지질 (cationic lipid)을 포함하는 지질나노입자 (Lipid nanoparticle, LNP)를 포함하는, 약물의 경폐 전달용 조성물이다.One aspect of the present invention for achieving the above object includes lipid nanoparticles (LNPs) containing ionizable lipids and cationic lipids represented by the following formula (1): , a composition for transpulmonary delivery of drugs.
[화학식 1][Formula 1]
본 발명에서 "이온화 가능 지질 (ionizable lipid)"은 용이하게 양성자화될 수 있는 아민-함유 지질을 의미하며, 지질 유사체 (lipidoid)로도 명명된다. 상기 이온화 가능 지질은, 주변 pH에 따라 전하상태가 변할 수 있으므로, 음이온성 약물과 정전기적 상호작용을 통하여 상기 약물이 지질나노입자 내에 높은 효율로 봉입되도록 하는 역할을 수행하며, 지질나노입자의 구조를 형성하는데 기여한다. 본 발명의 지질나노입자는 상기 화학식 1의 이온화 가능 지질을 포함하는 것을 하나의 특징으로 한다.In the present invention, “ionizable lipid” refers to an amine-containing lipid that can be easily protonated, and is also called a lipid analog (lipidoid). Since the charge state of the ionizable lipid can change depending on the surrounding pH, it plays a role in ensuring that the drug is encapsulated within the lipid nanoparticle with high efficiency through electrostatic interaction with the anionic drug, and the structure of the lipid nanoparticle contributes to forming One feature of the lipid nanoparticles of the present invention is that they contain an ionizable lipid of the above formula (1).
상기 화학식 1의 이온화 가능 지질은 복수 개의 3차 아민을 갖는 헤드 그룹과 에스터 작용기 및 탄소 이중결합을 포함하는 사슬 꼬리를 갖는 물질로서, 본 발명에서 "244-cis"로 명명된다. 본 발명자들은 국제공개공보 WO2023/136689에서, 244-cis 또는 이와 유사한 구조를 갖는 이온화 가능 지질은 지질나노입자의 일 구성으로 사용될 수 있고, 상기 지질나노입자는 mRNA와 같은 음이온성 약물 전달에 매우 우수한 효과가 있음을 보고한 바 있다. 그러나 본 발명자들은 상기 이온화 가능 지질이 놀랍게도 이와 조합되는 헬퍼 지질 (helper lipid)의 종류에 따라 표적 조직이 달라지며, 특히 양이온성 지질을 헬퍼 지질로 사용하여 지질나노입자를 제조하였을 때 폐 특이적으로 전달되는 것을 확인하였다. 또한, 본 발명의 지질나노입자는 면역원성이 거의 없이 mRNA를 안정적으로 전달하여 표적 부위에서 높은 수준으로 발현되는 것을 확인하였다.The ionizable lipid of Formula 1 is a substance having a head group having a plurality of tertiary amines, an ester functional group, and a chain tail containing a carbon double bond, and is named “244-cis” in the present invention. In International Publication WO2023/136689, the present inventors found that ionizable lipids with 244-cis or similar structures can be used as a component of lipid nanoparticles, and that the lipid nanoparticles are excellent for delivering anionic drugs such as mRNA. It has been reported that it is effective. However, the present inventors found that the target tissue of the ionizable lipid surprisingly varies depending on the type of helper lipid with which it is combined, and in particular, when lipid nanoparticles are manufactured using cationic lipid as a helper lipid, it is targeted specifically at the lungs. Delivery was confirmed. In addition, it was confirmed that the lipid nanoparticles of the present invention stably delivered mRNA with little immunogenicity and were expressed at a high level at the target site.
따라서, 본 발명은 화학식 1로 표시되는 이온화 가능 지질, 즉 244-cis 뿐만 아니라 이와 유사한 구조를 갖는 이온화 가능 지질에도 마찬가지로 적용될 수 있다. 당업자는 화학식 1의 이온화 가능 지질의 범위를 넘어, 예컨대 WO2023/136689에 기재된 다른 유사 구조의 이온화 가능 지질의 경우에도 본 발명에서 확인한 것과 마찬가지의 효과를 보여줄 수 있음을 충분히 기대할 수 있다. 그러므로, 상기 244-cis와 유사 구조의 이온화 가능 지질 역시 모두 균등 범위로서 본 발명의 범주 내로 포함될 수 있다. Therefore, the present invention can be applied not only to the ionizable lipid represented by Formula 1, that is, 244-cis, but also to the ionizable lipid having a similar structure. Those skilled in the art can fully expect that beyond the scope of the ionizable lipid of Formula 1, for example, other ionizable lipids with similar structures described in WO2023/136689 can show the same effects as those confirmed in the present invention. Therefore, all ionizable lipids with structures similar to 244-cis can also be included within the scope of the present invention as equivalents.
이에 제한되는 것은 아니나, 본 발명의 이온화 가능 지질은 하기 화학식 2로 표시되는 화합물일 수 있다.Although not limited thereto, the ionizable lipid of the present invention may be a compound represented by the following formula (2).
[화학식 2][Formula 2]
여기서, A는 
이고,Here, A is ego,
R1은 -C2-3알킬-NR2R3 또는 -C4-8알킬-(C=O)-Y-(CH2)xCH=CH-C5-6알킬이고,R 1 is -C 2-3 alkyl-NR 2 R 3 or -C 4-8 alkyl-(C=O)-Y-(CH 2 ) x CH=CH-C 5-6 alkyl,
R2 및 R3는 각각 독립적으로 -H, -C1-6알킬, 또는 -C4-8알킬-(C=O)-Y-(CH2)xCH=CH-C5-6알킬로부터 선택된 어느 하나이고,R 2 and R 3 are each independently selected from -H, -C 1-6 alkyl, or -C 4-8 alkyl-(C=O)-Y-(CH 2 ) x CH=CH-C 5-6 alkyl Which one is chosen,
Y는 -O- 또는 -NH-이고,Y is -O- or -NH-,
m은 1 내지 2의 정수이고,m is an integer from 1 to 2,
n은 3 내지 7의 정수이고,n is an integer from 3 to 7,
x는 1 내지 3의 정수이고,x is an integer from 1 to 3,
l은 3 내지 4의 정수이고, 및l is an integer from 3 to 4, and
p는 0 내지 2의 정수이다.p is an integer from 0 to 2.
또한, 본 발명의 구체예에 따르면, 상기 화학식 2로 표시되는 화합물은 하기 표 1에 기재된 화합물로 이루어진 군으로부터 선택된 것일 수 있다.Additionally, according to an embodiment of the present invention, the compound represented by Formula 2 may be selected from the group consisting of compounds shown in Table 1 below.
| 화합물compound | 구조structure |
|
1 One |
 |
|
2 2 |
 |
|
3 3 |
 |
|
4 4 |
 |
|
5 5 |
 |
|
6 6 |
 |
|
7 7 |
 |
|
8 8 |
 |
본 발명에 있어서, 용어 "알킬"은 다른 기재가 없는 한, 직쇄 또는 분지쇄의 비고리형 포화 탄화수소를 의미한다. 예를 들어, "C1-6알킬"은 탄소원자를 1 내지 6개 포함하는 알킬을 의미할 수 있다. 본 발명의 알킬 구조에서 단순한 치환기의 부가 등을 한 경우라도, 본 발명의 이온화 가능 지질과 동등한 효과를 가지는 한 모두 균등 범위로 본 발명의 범주에 포함된다.In the present invention, the term “alkyl” refers to a straight-chain or branched-chain acyclic saturated hydrocarbon, unless otherwise specified. For example, “C 1-6 alkyl” may mean alkyl containing 1 to 6 carbon atoms. Even in the case where a simple substituent is added to the alkyl structure of the present invention, as long as it has the same effect as the ionizable lipid of the present invention, it is included in the scope of the present invention to the extent of equivalents.
본 발명의 지질나노입자는 양이온성 지질 (cationic lipid)을 포함하는 것을 다른 하나의 특징으로 한다. 상기 양이온성 지질은 지질나노입자에서 헬퍼 지질 (helper lipid)에 해당하며 본 발명의 이온화 가능 지질과 함께 음이온성 약물이 폐 특이적으로 전달되도록 하는 역할을 수행한다.Another feature of the lipid nanoparticles of the present invention is that they contain cationic lipids. The cationic lipid corresponds to a helper lipid in lipid nanoparticles and, together with the ionizable lipid of the present invention, plays a role in delivering anionic drugs specifically to the lungs.
본 발명에 있어서, 용어 "헬퍼 지질 (helper lipid)"은 지질나노입자 내에서 이온화 가능 지질 및 약물이 상호 작용하여 형성된 코어를 감싸서 보호하는 역할을 수행하며, 타겟 세포의 인지질 이중층과 결합하여 약물의 세포 내 전달 시 세포막 통과 및 엔도좀 탈출 (endosomal escape)을 용이하게 한다. In the present invention, the term "helper lipid" serves to surround and protect the core formed by the interaction of ionizable lipids and drugs within lipid nanoparticles, and binds to the phospholipid bilayer of the target cell to protect the drug. When delivered intracellularly, it facilitates cell membrane passage and endosomal escape.
본 발명에 있어서, "양이온성 지질"은 DOTAP (1,2-dioleoyl-3-trimethylammonium propane) 또는 포스파티딜콜린 (phosphatidylcholine)일 수 있으나, 이에 제한되는 것은 아니다.In the present invention, the “cationic lipid” may be DOTAP (1,2-dioleoyl-3-trimethylammonium propane) or phosphatidylcholine, but is not limited thereto.
본 발명에 있어서, 용어 "포스파티딜콜린 (phosphatidylcholine)"은 인지질의 일종으로 헤드 그룹으로 콜린 (choline)이 포함된 화합물을 말한다. 동물, 식물, 효모, 및 곰팡이류에 널리 존재하며, 레시틴이라고도 한다. 포유동물의 막구성 인지질로서 주로 뇌수, 신경, 혈구, 난황 등에 들어 있다. 식물에서는 대두, 해바라기씨, 밀배아 등에 함유되어 있다. 일반적으로 글리세롤의 1번 위치에는 포화지방산, 2번 위치에는 불포화지방산이 결합되어 있는 것이 많다. 본 발명에서 포스파티딜콜린은 여러 구조의 포스파티딜콜린의 혼합물일 수 있고, 천연물 (예컨대, 난황, 대두 등)에서 분리된 것, 또는 화학적으로 합성된 것일 수 있다.In the present invention, the term "phosphatidylcholine" refers to a type of phospholipid and a compound containing choline as a head group. It is widely present in animals, plants, yeast, and molds, and is also called lecithin. It is a membrane phospholipid of mammals and is mainly contained in brain water, nerves, blood cells, and egg yolk. In plants, it is contained in soybeans, sunflower seeds, and wheat germ. In general, glycerol often has a saturated fatty acid bound to the 1st position and an unsaturated fatty acid bound to the 2nd position. In the present invention, phosphatidylcholine may be a mixture of phosphatidylcholine of various structures, may be isolated from natural products (e.g., egg yolk, soybeans, etc.), or may be chemically synthesized.
구체적인 하나의 양태로서, 본 발명의 지질나노입자는 DOTAP을 지질나노입자 전체를 기준으로 10 mol% 내지 70 mol%로 포함하는 것일 수 있고, 예를 들어 15 mol% 내지 70 mol%, 20 mol% 내지 70 mol%, 15 mol% 내지 65 mol%, 20 mol% 내지 65 mol%, 20 mol% 내지 60 mol%, 또는 20 mol% 내지 50 mol%일 수 있으나, 이에 제한되는 것은 아니다.In one specific embodiment, the lipid nanoparticles of the present invention may contain DOTAP in an amount of 10 mol% to 70 mol% based on the entire lipid nanoparticle, for example, 15 mol% to 70 mol%, 20 mol%. It may be from 70 mol%, 15 mol% to 65 mol%, 20 mol% to 65 mol%, 20 mol% to 60 mol%, or 20 mol% to 50 mol%, but is not limited thereto.
다른 구체적인 하나의 양태로서, 본 발명의 지질나노입자는 포스파티딜콜린을 지질나노입자 전체를 기준으로 10 mol% 내지 50 mol%, 15 mol% 내지 45 mol% 또는 20 mol% 내지 60 mol%로 포함하는 것일 수 있으나, 이에 제한되는 것은 아니다.In another specific embodiment, the lipid nanoparticles of the present invention contain 10 mol% to 50 mol%, 15 mol% to 45 mol%, or 20 mol% to 60 mol% of phosphatidylcholine based on the total lipid nanoparticles. However, it is not limited to this.
본 발명의 구체적인 실시예에서는 244-cis 이온화 가능 지질을 이용하여 지질나노입자를 제조하였을 때, 일반적으로는 거의 대부분 간으로 전달되지만 (도 4), DOTAP이나 포스파티딜콜린과 같은 양이온성 지질을 포함하였을 때에는 폐 특이적으로 전달되어 mRNA가 발현되는 것을 확인하였다 (도 5 내지 도 11). 따라서 본 발명의 화학식 1 (또는 화학식 2)로 표시되는 이온화 가능 지질 및 양이온성 지질을 포함하는 지질나노입자는 폐 조직에 특이적으로 전달되며, 이에 따라 높은 효율로 음이온성 약물을 폐에 특이적으로 전달할 수 있다.In a specific example of the present invention, when lipid nanoparticles are prepared using 244-cis ionizable lipids, they are generally mostly delivered to the liver (Figure 4), but when they contain cationic lipids such as DOTAP or phosphatidylcholine, It was confirmed that mRNA was expressed through lung-specific delivery (Figures 5 to 11). Therefore, lipid nanoparticles containing ionizable lipids and cationic lipids represented by Formula 1 (or Formula 2) of the present invention are specifically delivered to lung tissue, and thus deliver anionic drugs specifically to the lungs with high efficiency. It can be passed on.
본 발명의 지질나노입자는 구조적 지질 또는 PEG-지질을 더 포함할 수 있다.The lipid nanoparticles of the present invention may further include structural lipids or PEG-lipids.
상기 구조적 지질은 지질나노입자 내에서 입자 모양을 유지하고 나노입자의 코어 및 표면에 분산되어 나노입자의 안정성을 향상시키는 역할을 한다. 상기 구조적 지질은 예컨대, 콜레스테롤, 콜레스테놀, 스피나스테롤, 페코스테롤, 시토스테롤, 에르고스테롤, 에르고스테놀, 캄페스테롤, 스티그마스테롤, 브라시카스테롤, 토마티딘, 우르솔산, 알파-토코페롤 또는 이들의 혼합물일 수 있으나, 이에 제한되는 것은 아니다.The structural lipid maintains the particle shape within the lipid nanoparticle and is dispersed on the core and surface of the nanoparticle to improve the stability of the nanoparticle. The structural lipid is, for example, cholesterol, cholesterol, spinasterol, fecosterol, sitosterol, ergosterol, ergostenol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol or these. It may be a mixture of, but is not limited thereto.
상기 PEG-지질은 지질과 PEG가 컨쥬게이트된 형태를 지칭하는 것으로, 친수성 중합체인 폴리에틸렌글리콜 중합체가 결합된 지질을 의미한다. 상기 PEG-지질은 지질나노입자 내에서 나노입자의 혈청 내 입자 안정성에 기여하며, 나노입자 간 응집을 막는 역할을 수행한다. 또한, PEG-지질은 분해효소로부터 핵산을 보호하여 핵산의 체내 안정성을 강화시키며, 나노입자 내 봉입된 약물의 반감기를 증가시킬 수 있다. 상기 PEG-지질은 예컨대, PEG-세라마이드, PEG-DMG, PEG-c-DOMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, PEG-DSPE 또는 이들의 혼합물일 수 있고, 구체적으로 C16-PEG2000 세라마이드이나, 이에 제한되는 것은 아니다.The PEG-lipid refers to a conjugated form of lipid and PEG, and refers to a lipid to which polyethylene glycol polymer, a hydrophilic polymer, is bound. The PEG-lipid within lipid nanoparticles contributes to particle stability in serum and plays a role in preventing aggregation between nanoparticles. In addition, PEG-lipids protect nucleic acids from degrading enzymes, enhance the stability of nucleic acids in the body, and can increase the half-life of drugs encapsulated in nanoparticles. The PEG-lipid may be, for example, PEG-ceramide, PEG-DMG, PEG-c-DOMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, PEG-DSPE or mixtures thereof, specifically C16-PEG2000 ceramide. However, it is not limited to this.
구체적인 하나의 양태로서, 본 발명의 이온화 가능 지질과 DOTAP, 구조적 지질 및 PEG-지질을 혼합하여 지질나노입자를 제조할 경우, 이온화 가능 지질 : DOTAP : 구조적 지질 : PEG-지질의 몰비는 10 내지 40 : 5 내지 80 : 5 내지 80 : 1 내지 5일 수 있다. 더 구체적으로, 상기 몰비는 20 내지 30 : 10 내지 70 : 10 내지 70 : 1 내지 5일 수 있으며, 더 구체적으로는 20 내지 30 : 15 내지 70 : 15 내지 70 : 1 내지 3일 수 있으나, 이에 제한되지 않는다.In one specific embodiment, when lipid nanoparticles are prepared by mixing the ionizable lipid of the present invention with DOTAP, structural lipid, and PEG-lipid, the molar ratio of ionizable lipid: DOTAP: structural lipid: PEG-lipid is 10 to 40. : 5 to 80 : 5 to 80 : 1 to 5. More specifically, the molar ratio may be 20 to 30: 10 to 70: 10 to 70: 1 to 5, and more specifically, 20 to 30: 15 to 70: 15 to 70: 1 to 3. Not limited.
다른 구체적인 하나의 양태로서, 본 발명의 이온화 가능 지질과 포스파티딜콜린, 구조적 지질 및 PEG-지질을 혼합하여 지질나노입자를 제조할 경우, 이온화 가능 지질 : 포스파티딜콜린 : 구조적 지질 : PEG-지질의 몰비는 10 내지 40 : 5 내지 80 : 5 내지 80 : 1 내지 5일 수 있다. 더 구체적으로, 상기 몰비는 20 내지 30 : 10 내지 50 : 30 내지 60 : 1 내지 5일 수 있으며, 더 구체적으로는 20 내지 30 : 20 내지 40 : 30 내지 60 : 1 내지 3일 수 있으나, 이에 제한되지 않는다.In another specific embodiment, when lipid nanoparticles are prepared by mixing the ionizable lipid of the present invention with phosphatidylcholine, structural lipid, and PEG-lipid, the molar ratio of ionizable lipid: phosphatidylcholine: structural lipid: PEG-lipid is 10 to 10. It may be 40:5 to 80:5 to 80:1 to 5. More specifically, the molar ratio may be 20 to 30:10 to 50:30 to 60:1 to 5, and more specifically, 20 to 30:20 to 40:30 to 60:1 to 3. Not limited.
본 발명의 지질나노입자는 산성 pH 조건에서 양전하를 나타내므로 음전하를 나타내는 핵산, 약물 등의 치료제와 정전기적 상호작용을 통해 용이하게 약물과의 복합체를 형성하여 높은 효율로 음이온성 약물을 봉입할 수 있으며, 약물의 세포 내 또는 생체 내 약물 전달 조성물로서 사용될 수 있다. 따라서 본 발명의 지질나노입자는 핵산뿐만 아니라 음이온을 띄는 모든 형태의 약물의 전달에 유용하게 사용될 수 있다. 즉, 본 발명의 지질나노입자는 최종적으로 음이온성 약물을 추가로 포함하는 형태 (봉입된 형태)로 제조될 수 있고, 봉입된 음이온성 약물을 폐에 특이적으로 전달할 수 있다.Since the lipid nanoparticles of the present invention exhibit a positive charge under acidic pH conditions, they can easily form a complex with the drug through electrostatic interaction with therapeutic agents such as nucleic acids and drugs that exhibit a negative charge, allowing the encapsulation of anionic drugs with high efficiency. It can be used as an intracellular or in vivo drug delivery composition. Therefore, the lipid nanoparticles of the present invention can be useful for the delivery of not only nucleic acids but also all types of drugs with anionic properties. That is, the lipid nanoparticles of the present invention can ultimately be manufactured in a form (encapsulated form) that additionally contains an anionic drug, and the encapsulated anionic drug can be specifically delivered to the lungs.
본 발명에서, 용어 "봉입 (encapsulation)"은 전달물질을 둘러싸서 효율적으로 생체 내로 함입시키기 위해 캡슐화하는 것을 말하고, 약물 봉입률 (캡슐화 효율, Encapsulation efficiency)은 제조에 사용된 전체 약물 함량에 대하여 지질나노입자 내에 봉입된 약물의 함량을 의미한다.In the present invention, the term "encapsulation" refers to encapsulating the delivery material to surround it and efficiently incorporate it into the body, and the drug encapsulation efficiency (encapsulation efficiency) refers to the lipid content relative to the total drug content used in manufacturing. It refers to the content of drug encapsulated in nanoparticles.
상기 음이온성 약물은 핵산, 저분자 화합물, 펩타이드, 단백질, 단백질-핵산 구조체 또는 음이온성 생체고분자-약물 접합체 등일 수 있으나, 본 발명의 이온화 가능 지질과 함께 지질나노입자를 형성하여 안정적이고 효율적으로 전달될 수 있는 한 이에 제한되는 것은 아니다.The anionic drug may be a nucleic acid, low molecular weight compound, peptide, protein, protein-nucleic acid structure, or anionic biopolymer-drug conjugate, but may be stably and efficiently delivered by forming lipid nanoparticles together with the ionizable lipid of the present invention. It is not limited to this as long as possible.
본 발명에서 상기 핵산은 소간섭 리보핵산 (siRNA), 리보좀 리보핵산 (rRNA), 디옥시리보핵산 (DNA), 상보성 디옥시리보핵산 (cDNA), 앱타머 (aptamer), 전령 리보핵산 (mRNA), 운반 리보핵산 (tRNA), sgRNA, 안티센스 올리고뉴클레오티드, shRNA, miRNA, 리보자임 (ribozyme), PNA, 및 DNAzyme, 또는 이들의 혼합물일 수 있으나, 이에 제한되는 것은 아니다.In the present invention, the nucleic acids include small interfering ribonucleic acid (siRNA), ribosomal ribonucleic acid (rRNA), deoxyribonucleic acid (DNA), complementary deoxyribonucleic acid (cDNA), aptamer, messenger ribonucleic acid (mRNA), and transport ribonucleic acid. It may be (tRNA), sgRNA, antisense oligonucleotide, shRNA, miRNA, ribozyme, PNA, and DNAzyme, or a mixture thereof, but is not limited thereto.
상기 지질나노입자에서 총 지질/핵산의 중량비는 1 내지 30일 수 있으며, 구체적으로 5 내지 27, 보다 구체적으로 10 내지 23일 수 있으나, 이에 제한되는 것은 아니다.The weight ratio of total lipid/nucleic acid in the lipid nanoparticles may be 1 to 30, specifically 5 to 27, and more specifically 10 to 23, but is not limited thereto.
본 발명의 다른 하나의 양태는, 상기 화학식 1의 이온화 가능 지질 및 양이온성 지질을 포함하는 지질나노입자, 및 음이온성 약물을 유효성분으로 포함하는, 폐 질환의 예방 또는 치료용 약학적 조성물이다.Another aspect of the present invention is a pharmaceutical composition for preventing or treating lung disease, comprising lipid nanoparticles containing the ionizable lipid and cationic lipid of Formula 1 above, and an anionic drug as an active ingredient.
본 발명의 또 다른 하나의 양태는, 상기 조성물을 이를 필요로 하는 개체에 투여하는 단계를 포함하는, 폐 질환의 치료 방법이다.Another aspect of the present invention is a method of treating lung disease, comprising administering the composition to an individual in need thereof.
본 발명의 또 다른 하나의 양태는, 폐 질환의 예방 또는 치료에 사용하기 위한 약학적 조성물, 또는 폐 질환의 예방 또는 치료를 위한 상기 조성물의 용도이다.Another aspect of the present invention is a pharmaceutical composition for use in the prevention or treatment of lung disease, or use of the composition for the prevention or treatment of lung disease.
지질나노입자 및 음이온성 약물에 대해서는 상기 설명한 바와 같다.Lipid nanoparticles and anionic drugs are as described above.
본 발명의 지질나노입자는 핵산 등의 음이온성 약물과 안정된 복합체를 형성하고 낮은 세포독성 및 효과적인 세포 흡수성을 나타내므로, 음이온성 약물을 전달하는데 효과적이다. 또한, 상기 지질나노입자는 투여 시 폐에 특이적으로 전달될 수 있으므로, 폐 질환의 예방 또는 치료에 유용하게 활용될 수 있다.The lipid nanoparticles of the present invention form a stable complex with anionic drugs such as nucleic acids and exhibit low cytotoxicity and effective cell absorption, so they are effective in delivering anionic drugs. In addition, since the lipid nanoparticles can be specifically delivered to the lungs when administered, they can be useful in preventing or treating lung diseases.
본 발명의 지질나노입자는 폐를 표적으로 하여 약물을 특이적으로 전달할 수 있으며, 본 발명의 목적 상 사용되는 음이온성 약물의 종류, 핵산의 종류, 핵산 서열에 따라 다양한 폐 질환에 대한 예방 또는 치료 효과를 기대할 수 있다. 즉, 본 발명에서 폐 질환의 종류는 제한되지 않는다. 따라서, 상기 폐 질환은 예를 들어, 폐기종, 천식, 폐렴, 결핵, 폐 고혈압, 폐암, 신생아 기관지폐 형성 장애증, 만성 폐쇄성 폐질환, 급성 기관지염, 만성 기관지염, 세기관지염, 기관지 확장증, 과민증, 폐실질 염, 급성 연기 흡입, 열에 의한 폐 손상, 낭포성 섬유증, 허파꽈리 단백증, 알파-1-프로테아제 결핍, 폐 염증성 장애, 급성 호흡 곤란 증후군, 급성 폐 손상, 특발성 호흡 곤란 증후군 및 폐 섬유증으로 이루어진 군에서 선택된 1종 이상일 수 있으며, 구체적으로는 폐 섬유증일 수 있으나, 이에 제한되지 않는다.The lipid nanoparticles of the present invention can specifically deliver drugs by targeting the lungs, and for the purpose of the present invention, prevent or treat various lung diseases depending on the type of anionic drug, type of nucleic acid, and nucleic acid sequence used. Effects can be expected. That is, in the present invention, the type of lung disease is not limited. Therefore, the lung diseases include, for example, emphysema, asthma, pneumonia, tuberculosis, pulmonary hypertension, lung cancer, neonatal bronchopulmonary dysplasia, chronic obstructive pulmonary disease, acute bronchitis, chronic bronchitis, bronchiolitis, bronchiectasis, hypersensitivity, lung parenchyma. A group consisting of salts, acute smoke inhalation, heat-induced lung injury, cystic fibrosis, alveolar proteinosis, alpha-1-protease deficiency, pulmonary inflammatory disorders, acute respiratory distress syndrome, acute lung injury, idiopathic respiratory distress syndrome, and pulmonary fibrosis. It may be one or more types selected from, and specifically may be pulmonary fibrosis, but is not limited thereto.
본 발명에서 용어, "치료"는 질병을 갖는 개개인 또는 세포의 천연 과정을 변경시키기 위해 개입하는 것을 지칭하고, 이는 병리 상태가 진행되는 동안 또는 이를 예방하기 위해 수행될 수 있다. 목적하는 치료 효과에는 질병의 발생 또는 재발을 예방하고, 증상을 완화시키며, 질병에 따른 모든 직접 또는 간접적인 병리학적 결과를 저하시키며, 전이를 예방하고, 질병 진행 속도를 감소시키며, 질병 상태를 경감 또는 일시적 완화시키며, 차도시키거나 예후를 개선시키는 것이 포함된다. 특히, 본 발명에서는 이온화 가능 지질 및 양이온성 지질을 포함하는 지질나노입자 및 음이온성 약물을 유효성분으로 포함하는 조성물의 투여로 폐 관련 질환의 경과를 호전시키는 모든 행위를 포함한다. 또한, 용어 "예방"은 상기 지질나노입자의 투여로 질병의 발병을 억제 또는 지연시키는 모든 행위를 말한다. 본 발명의 지질나노입자가 치료 또는 예방 목적으로 사용될 경우, 개체에 치료학적으로 유효한 양으로 투여된다.In the present invention, the term “treatment” refers to intervention to alter the natural processes of an individual or cell with a disease, which may be performed during the progression of the pathology or to prevent it. The desired therapeutic effects include preventing the occurrence or recurrence of the disease, alleviating symptoms, reducing all direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, and alleviating the disease state. Or it includes temporary relief, remission, or improvement of prognosis. In particular, the present invention includes all actions to improve the course of lung-related diseases by administering a composition containing lipid nanoparticles containing ionizable lipids and cationic lipids and anionic drugs as active ingredients. Additionally, the term “prevention” refers to all actions that suppress or delay the onset of a disease by administering the lipid nanoparticles. When the lipid nanoparticles of the present invention are used for treatment or prevention purposes, they are administered to an individual in a therapeutically effective amount.
본 발명에서 사용되는 "치료학적으로 유효한 양"이라는 용어는 음이온성 약물 함유 지질나노입자의 유효한 양을 나타낸다. 구체적으로, "치료학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 개체 종류 및 중증도, 연령, 성별, 질병의 종류, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 약학적 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 시판되는 치료제와는 순차적으로 또는 동시에 투여될 수 있다. 그리고 단일 또는 다중 투여될 수 있다. 상기 요소를 모두 고려하여 부작용없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 당업자에 의해 용이하게 결정될 수 있다. 본 발명의 약학적 조성물의 투여 용량은 환자의 상태, 연령, 성별 및 합병증 등의 다양한 요인에 따라 전문가에 의해 결정될 수 있다. 본 발명의 조성물의 유효성분은 안전성이 우수하므로, 결정된 투여 용량 이상으로도 사용될 수 있다.The term “therapeutically effective amount” used in the present invention refers to an effective amount of anionic drug-containing lipid nanoparticles. Specifically, "therapeutically effective amount" means an amount sufficient to treat the disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is determined by the type and severity of the individual, age, gender, type of disease, It can be determined based on factors including the activity of the drug, sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, drugs used simultaneously, and other factors well known in the medical field. The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with commercially available therapeutic agents. And it can be administered single or multiple times. Considering all of the above factors, it is important to administer an amount that can achieve maximum effect with the minimum amount without side effects, and can be easily determined by a person skilled in the art. The administered dose of the pharmaceutical composition of the present invention may be determined by an expert depending on various factors such as the patient's condition, age, gender, and complications. Since the active ingredient of the composition of the present invention has excellent safety, it can be used beyond the determined administration dose.
상기 지질나노입자를 포함하는 조성물은 경구, 근육, 정맥, 동맥, 피하, 복강, 폐, 및 비강 주사 등으로 투여될 수 있으며, 구체적으로 정맥 투여될 수 있으나, 이에 제한되지 않는다.The composition containing the lipid nanoparticles may be administered orally, intramuscularly, intravenously, arterially, subcutaneously, intraperitoneally, pulmonaryly, and intranasally, and may specifically be administered intravenously, but is not limited thereto.
본 발명의 조성물은 투여를 위해서 추가로 약학적으로 허용가능한 담체를 1 종 이상 더 포함할 수 있다. 약학적으로 허용 가능한 담체는 식염수, 멸균수, 링거액, 완충 식염수, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 하나 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다.The composition of the present invention may further include one or more pharmaceutically acceptable carriers for administration. Pharmaceutically acceptable carriers can be saline solution, sterile water, Ringer's solution, buffered saline solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and a mixture of one or more of these ingredients, and if necessary, antioxidants, buffer solutions, Other common additives such as bacteriostatic agents can be added.
이하, 실시예를 통하여 본 발명의 구성 및 효과를 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것일 뿐 본 발명의 범위가 이들 실시예에 의해 제한되는 것은 아니다.Hereinafter, the configuration and effects of the present invention will be described in more detail through examples. These examples are only for illustrating the present invention and the scope of the present invention is not limited by these examples.
실시예 1: 경폐 전달용 지질나노입자의 제조Example 1: Preparation of lipid nanoparticles for transpulmonary delivery
이온화 가능 지질로서 244-cis (WO2023/136689 참조)를 준비하였으며, 하기의 반응식 1에 따라 합성하였다. 본 발명에서 244-cis를 포함하는 지질나노입자는 '244-cis 지질나노입자'로 명명하였다. 대조군으로 SM-102 또는 MC3를 사용하였다.244-cis (see WO2023/136689) was prepared as an ionizable lipid and synthesized according to Scheme 1 below. In the present invention, lipid nanoparticles containing 244-cis were named '244-cis lipid nanoparticles'. SM-102 or MC3 was used as a control.
[반응식 1][Scheme 1]
이온화 가능 지질, 양이온성 지질 (DOTAP, 1,2-dioleoyl-3-trimethylammonium propane; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; 또는 EPC, egg phosphatidylcholine (Avanti, 890704P), 콜레스테롤 (Cholesterol powder, BioReagent, 세포 배양용, ≥99%, sigma, 한국), 및 C16-PEG2000 세라마이드 (Avanti, 미국)를 에탄올에 26.5 : 10 내지 60 : 12 내지 62 : 1.5의 몰비 (표 2)로 용해시켰다.Ionizable lipids, cationic lipids (DOTAP, 1,2-dioleoyl-3-trimethylammonium propane; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; or EPC, egg phosphatidylcholine (Avanti, 890704P), cholesterol ( Cholesterol powder, BioReagent, for cell culture, ≥99%, Sigma, Korea), and C16-PEG2000 ceramide (Avanti, USA) were dissolved in ethanol at a molar ratio of 26.5:10 to 60:12 to 62:1.5 (Table 2). I ordered it.
| 성분ingredient | 함량 (mol%)Content (mol%) | |||
| 이온화 가능 지질ionizable lipids | 26.526.5 | 26.526.5 | 26.526.5 | 26.526.5 |
|
양이온성 지질 |
1010 | 2020 | 4040 | 6060 |
| 콜레스테롤cholesterol | 6262 | 5252 | 3232 | 1212 |
| PEG-지질PEG-lipid | 1.51.5 | 1.51.5 | 1.51.5 | 1.51.5 |
이온화 가능 지질, 콜레스테롤, 양이온성 지질, 및 PEG-세라마이드 접합체가 용해된 에탄올 및 핵산 (mRNA)이 용해된 수성상 (아세테이트산 나트륨 또는 시트르산 나트륨)을 1 : 3의 부피비로 12 ml/min의 유속으로 미세유체 혼합 장치 (Benchtop Nanoassemblr; PNI, Canada)를 통해 혼합하여 지질나노입자를 제조하였다. mRNA : 이온화 가능 지질의 중량비는 1 : 20으로 하였다.Ionizable lipids, cholesterol, cationic lipids, and PEG-ceramide conjugates were dissolved in ethanol and nucleic acids (mRNA) were dissolved in aqueous phase (sodium acetate or sodium citrate) at a volume ratio of 1:3 at a flow rate of 12 ml/min. Lipid nanoparticles were prepared by mixing using a microfluidic mixing device (Benchtop Nanoassemblr; PNI, Canada). The weight ratio of mRNA:ionizable lipid was 1:20.
제조된 지질나노입자에서 에탄올 제거 및 체내의 pH와 지질나노입자의 pH를 맞추기 위해서, 3500 MWCO 투석 카세트를 사용하여 16 시간 동안 PBS에 대해 투석하였다.In order to remove ethanol from the prepared lipid nanoparticles and adjust the pH of the lipid nanoparticles to that of the body, they were dialyzed against PBS for 16 hours using a 3500 MWCO dialysis cassette.
실험예 1: 244-cis를 포함하는 지질나노입자의 전달 효능 확인Experimental Example 1: Confirmation of delivery efficacy of lipid nanoparticles containing 244-cis
실험예 1-1. mRNA 발현 확인Experimental Example 1-1. Confirmation of mRNA expression
hEPO mRNA (서열번호 1)가 봉입되고, 244-cis, DOPE (20 mol%), 콜레스테롤 및 PEG-지질을 포함하는 지질나노입자를 mRNA 기준 0.1 mg/kg 용량으로 7 주령 Balb/c 마우스에 정맥 주사하였다. 3, 6, 9, 24 및 48 시간 뒤에 혈액을 채취하여, ELISA (R&D systems, USA)를 사용하여 hEPO 단백질 발현을 확인하였다 (도 1).hEPO mRNA (SEQ ID NO: 1) was encapsulated, and lipid nanoparticles containing 244-cis, DOPE (20 mol%), cholesterol, and PEG-lipid were administered intravenously to 7-week-old Balb/c mice at a dose of 0.1 mg/kg based on mRNA. Injected. Blood was collected after 3, 6, 9, 24, and 48 hours, and hEPO protein expression was confirmed using ELISA (R&D systems, USA) (Figure 1).
그 결과, 244-cis를 포함하는 지질나노입자는 핵산을 생체 내로 효과적으로 전달하고 발현시켜 혈액 내에서 hEPO가 상당한 수준으로 검출되었다. 244-cis를 포함하는 지질나노입자는 대조군인 MC3 LNP 대비 현저히 높은 수준을 나타내며, SM-102 LNP와 동등한 수준을 나타내었다.As a result, lipid nanoparticles containing 244-cis effectively delivered and expressed nucleic acids in vivo, and hEPO was detected at a significant level in the blood. Lipid nanoparticles containing 244-cis showed a significantly higher level than the control MC3 LNP, and showed a level equivalent to that of SM-102 LNP.
실험예 1-2. MCP-1 분비 확인Experimental Example 1-2. Confirmation of MCP-1 secretion
상기 실험예 1-1.의 지질나노입자를 mRNA 기준 0.5 mg/kg 용량으로 7주령 Balb/c 마우스에 정맥 주사하고, 3 시간 뒤에 혈액을 채취하였다. ELISA (Invitrogen, USA)를 사용하여 MCP-1 단백질 발현을 확인하였다 (도 2).The lipid nanoparticles of Experimental Example 1-1 were injected intravenously into 7-week-old Balb/c mice at a dose of 0.5 mg/kg based on mRNA, and blood was collected 3 hours later. MCP-1 protein expression was confirmed using ELISA (Invitrogen, USA) (Figure 2).
그 결과, 도 2에 나타난 바와 같이, 244-cis를 포함하는 지질나노입자는 SM-102 LNP 및 MC3 LNP와 비교하여 현저히 낮은 MCP-1 발현을 나타내는 것을 확인하였다.As a result, as shown in Figure 2, it was confirmed that lipid nanoparticles containing 244-cis showed significantly lower MCP-1 expression compared to SM-102 LNP and MC3 LNP.
실험예 1-3. DOTAP에 의한 MCP-1 분비 확인Experimental Example 1-3. Confirmation of MCP-1 secretion by DOTAP
상기 실험예 1-1.의 244-cis 지질나노입자에서 DOPE를 DOTAP으로 교체한 지질나노입자를 mRNA 기준 0.5 mg/kg 용량으로 7 주령 Balb/c 마우스에 정맥 주사하고, 6 시간 뒤에 혈액을 채취하였다. ELISA (Invitrogen, USA)를 사용하여 MCP-1 단백질 발현을 확인하였다 (도 3).Lipid nanoparticles in which DOPE was replaced with DOTAP in the 244-cis lipid nanoparticles of Experimental Example 1-1 above were injected intravenously into 7-week-old Balb/c mice at a dose of 0.5 mg/kg based on mRNA, and blood was collected 6 hours later. did. MCP-1 protein expression was confirmed using ELISA (Invitrogen, USA) (Figure 3).
그 결과, 도 3에 나타난 바와 같이, DOPE를 DOTAP으로 대체하더라도 기존 244-cis 제형의 MCP-1 분비 정도와 통계적으로 유의미한 차이는 보이지 않았다.As a result, as shown in Figure 3, even if DOPE was replaced with DOTAP, there was no statistically significant difference from the level of MCP-1 secretion in the existing 244-cis formulation.
실험예 2: fLuc mRNA를 이용한 244-cis 지질나노입자의 폐 특이적 전달 확인Experimental Example 2: Confirmation of lung-specific delivery of 244-cis lipid nanoparticles using fLuc mRNA
실험예 2-1. DOTAP의 폐 전달 효능 확인Experimental Example 2-1. Confirmation of pulmonary delivery efficacy of DOTAP
fLuciferase mRNA (서열번호 2)가 봉입되고, 244-cis, DOTAP, 콜레스테롤 및 PEG-지질을 포함하는 지질나노입자를 표 2의 함량 별로 제조하고, mRNA 기준 0.2 mg/kg 용량으로 7 주령 C57BL/6 마우스에 정맥 주사하였다. 6 시간 뒤에 루시페린 (luciferin) 0.25 mg/kg을 복강 투여하여 IVIS (PerkinElmer, USA) 장비를 통해 탈체 기관 이미지 (ex vivo organ image)로 생체발광을 확인하였다 (도 4 내지 도 8). 대조군으로 DOPE 함유 지질나노입자를 사용하였다.fLuciferase mRNA (SEQ ID NO: 2) was encapsulated and lipid nanoparticles containing 244-cis, DOTAP, cholesterol, and PEG-lipid were prepared according to the contents in Table 2, and administered to 7-week-old C57BL/6 at a dose of 0.2 mg/kg based on mRNA. It was injected intravenously into mice. Six hours later, 0.25 mg/kg of luciferin was administered intraperitoneally, and bioluminescence was confirmed through ex vivo organ images using IVIS (PerkinElmer, USA) equipment (FIGS. 4 to 8). As a control, DOPE-containing lipid nanoparticles were used.
그 결과, 20 mol% DOPE를 포함하는 경우 간에서 높은 발광 강도를 나타내었으나 (도 4), DOPE를 DOTAP으로 대체한 경우 mRNA가 폐로 전달되어 발현되는 것을 확인할 수 있었다 (도 5 내지 도 9). 특히, DOTAP을 20 내지 60 mol%로 포함할 경우 폐 특이적으로 높은 발광 강도를 나타내었다 (도 6 내지 도 9). 이를 통해, 이온화 가능 지질 244-cis는 양이온성 지질로서 DOTAP을 포함하여 지질나노입자를 제조하였을 때 폐 특이적으로 전달된다는 것을 알 수 있었다.As a result, when 20 mol% DOPE was included, high luminescence intensity was shown in the liver (Figure 4), but when DOPE was replaced with DOTAP, it was confirmed that the mRNA was delivered to the lungs and expressed (Figures 5 to 9). In particular, when DOTAP was included at 20 to 60 mol%, high lung-specific luminescence intensity was observed ( FIGS. 6 to 9 ). Through this, it was found that the ionizable lipid 244-cis was delivered specifically to the lungs when lipid nanoparticles were prepared including DOTAP as a cationic lipid.
실험예 2-2. 포스파티딜콜린의 폐 전달 효능 확인Experimental Example 2-2. Confirmation of pulmonary delivery efficacy of phosphatidylcholine
244-cis 및 포스파티딜콜린 (EPC)을 함유하는 지질나노입자를 표 2의 함량 별로 제조하고, mRNA 0.1 mg/kg을 7 주령 C57BL/6 마우스에 정맥 주사하였다. 6 시간 뒤에 루시페린 (luciferin) 0.25 mg/kg을 복강 투여하여 IVIS (PerkinElmer, USA) 장비를 통해 탈체 기관 이미지 (ex vivo organ image)로 생체발광을 확인하였다 (도 10 및 도 11).Lipid nanoparticles containing 244-cis and phosphatidylcholine (EPC) were prepared according to the contents in Table 2, and 0.1 mg/kg of mRNA was injected intravenously into 7-week-old C57BL/6 mice. Six hours later, 0.25 mg/kg of luciferin was administered intraperitoneally, and bioluminescence was confirmed through ex vivo organ images using IVIS (PerkinElmer, USA) equipment (FIGS. 10 and 11).
그 결과, DOTAP과 마찬가지로 포스파티딜콜린을 포함하는 244-cis 지질나노입자는 폐 특이적으로 높은 발광 강도를 나타내었다.As a result, like DOTAP, 244-cis lipid nanoparticles containing phosphatidylcholine showed high lung-specific luminescence intensity.
실험예 3: Cre mRNA를 이용한 244-cis 지질나노입자의 폐 세포별 전달 효율 확인Experimental Example 3: Confirmation of delivery efficiency of 244-cis lipid nanoparticles to lung cells using Cre mRNA
본 발명의 지질나노입자의 폐 세포별 전달 효과를 확인하기 위해, Cre 단백질을 이용하여 Tomato 단백질을 발현하는 LSL-tdTomato 마우스 (The Jackson Laboratory #:007914)를 사용하였다. Cre mRNA (서열번호 3)가 봉입되고, 244-cis, DOTAP (20 mol%), 콜레스테롤 및 PEG-지질을 포함하는 지질나노입자를 mRNA 기준 0.3 mg/kg 용량으로 7 주령 LSL-tdTomato 마우스에 4 일 간격으로 2 번 정맥 주사하였다. 2 차 주사 2 일 후에 폐 조직 세포를 분리하여 유세포 분석 (LSRFortessa, BD)을 이용하여 폐 세포별 (내피 세포, 섬유아세포, 상피 세포, 면역 세포) tdTomato 형광 발현을 확인하였다 (도 12). 내피 세포 염색을 위해 APC 항-마우스 CD31 항체 (BioLegend; 102409), 면역 세포 염색을 위해 FITC 항-마우스 CD45.2 항체 (BioLegend; 109805), 상피 세포 염색을 위해 PE/Cyanine7 항-마우스 CD326 항체 (BioLegend; 118216), 섬유아세포 염색을 위해 PE/Cyanine7 항-마우스 CD140a 항체 (BioLegend; 135911)를 사용하였다.To confirm the delivery effect of the lipid nanoparticles of the present invention to lung cells, LSL-tdTomato mice (The Jackson Laboratory #: 007914), which express Tomato protein using Cre protein, were used. Cre mRNA (SEQ ID NO: 3) was encapsulated and lipid nanoparticles containing 244-cis, DOTAP (20 mol%), cholesterol, and PEG-lipid were administered to 7-week-old LSL-tdTomato mice at a dose of 0.3 mg/kg based on mRNA. It was administered intravenously twice at daily intervals. Two days after the second injection, lung tissue cells were isolated and tdTomato fluorescence expression in each lung cell (endothelial cells, fibroblasts, epithelial cells, immune cells) was confirmed using flow cytometry (LSRFortessa, BD) (Figure 12). APC anti-mouse CD31 antibody (BioLegend; 102409) for staining endothelial cells, FITC anti-mouse CD45.2 antibody (BioLegend; 109805) for staining immune cells, and PE/Cyanine7 anti-mouse CD326 antibody (BioLegend; 109805) for staining epithelial cells. BioLegend; 118216), and PE/Cyanine7 anti-mouse CD140a antibody (BioLegend; 135911) was used to stain fibroblasts.
그 결과, 모든 유형의 폐 세포에서 대조군인 MC3 LNP에 비해 압도적으로 높은 발현을 나타내어, 본 발명의 지질나노입자의 우수한 폐 전달 효과를 확인하였다. 세포 유형 별로 보면, 내피 세포에서 80 % 이상의 tdTomato 발현을 확인하였으며, 상피 세포, 면역 세포, 섬유아세포에서 약 20 %의 tdTomato 발현을 확인하였다.As a result, all types of lung cells showed overwhelmingly higher expression than the control MC3 LNP, confirming the excellent lung delivery effect of the lipid nanoparticles of the present invention. By cell type, more than 80% of tdTomato expression was confirmed in endothelial cells, and about 20% of tdTomato expression was confirmed in epithelial cells, immune cells, and fibroblasts.
실험예 4: 폐 섬유화 모델에서 244-cis 지질나노입자의 폐 특이적 전달 확인Experimental Example 4: Confirmation of lung-specific delivery of 244-cis lipid nanoparticles in lung fibrosis model
질환 모델에서 본 발명의 지질나노입자의 효능을 확인하기 위하여, 블레오마이신 1.8 mg/kg을 처리하여 14 일 후 폐 섬유화가 일어난 7 주령 LSL-tdTomato 마우스를 준비하였다. 상기 실험예 3의 244-cis 지질나노입자를 폐 섬유화가 일어난 7 주령 LSL-tdTomato 마우스에 mRNA 기준 0.3 mg/kg 용량으로, 4 일 간격으로 2 번 정맥 주사하였다. 2 차 주사 2 일 후에 폐 조직 세포를 분리하고 유세포 분석 (LSRFortessa, BD)을 이용하여 폐 세포별 (내피 세포, 섬유아세포, 상피 세포, 면역 세포) tdTomato 형광 발현을 확인하였다 (도 13 및 도 14).In order to confirm the efficacy of the lipid nanoparticles of the present invention in a disease model, 7-week-old LSL-tdTomato mice, which developed lung fibrosis 14 days after treatment with 1.8 mg/kg of bleomycin, were prepared. The 244-cis lipid nanoparticles of Experimental Example 3 were injected intravenously twice at 4-day intervals at a dose of 0.3 mg/kg based on mRNA into 7-week-old LSL-tdTomato mice with lung fibrosis. Two days after the secondary injection, lung tissue cells were isolated and tdTomato fluorescence expression was confirmed in each lung cell (endothelial cells, fibroblasts, epithelial cells, immune cells) using flow cytometry (LSRFortessa, BD) (Figures 13 and 14 ).
세포 유형별 염색을 위해 상기 실험예 3과 같은 조건에 더하여, 섬유아세포 subtype 염색을 위해 Brilliant Violet 421™ 항-마우스 CD90.1 항체 (BioLegend; 202529), 및 FITC 항-마우스 Sca-1 항체 (BioLegend; 122505)를 사용하였다.In addition to the same conditions as in Experimental Example 3 for staining by cell type, Brilliant Violet 421™ anti-mouse CD90.1 antibody (BioLegend; 202529), and FITC anti-mouse Sca-1 antibody (BioLegend; 202529) were used for fibroblast subtype staining. 122505) was used.
그 결과, 섬유화 질환을 유발하지 않은 마우스에서와 마찬가지로 본 발명의 지질나노입자는 모든 유형의 폐 세포에서 대조군인 MC3 LNP에 비해 압도적으로 높은 발현을 나타내었다. 또한, 내피 세포에서 80 % 이상의 tdTomato 발현을 나타내었으며, 상피 세포, 면역 세포 및 섬유아세포에서도 약 30 % 수준의 tdTomato 발현을 나타내었다 (도 13). 섬유아세포에서 tdTomato의 발현 수준을 확인하였을 때 MC3 LNP의 경우 거의 발현이 나타나지 않았으나, 244-cis LNP의 경우 특히 Sca-1+ 섬유아세포에서 40 % 이상의 tdTomato 발현을 나타내었다 (도 14).As a result, as in mice that did not develop fibrotic disease, the lipid nanoparticles of the present invention showed overwhelmingly higher expression than the control MC3 LNP in all types of lung cells. In addition, endothelial cells showed over 80% tdTomato expression, and epithelial cells, immune cells, and fibroblasts also showed tdTomato expression at a level of about 30% (Figure 13). When checking the expression level of tdTomato in fibroblasts, almost no expression was observed in the case of MC3 LNPs, but in the case of 244-cis LNPs, tdTomato expression was shown by more than 40%, especially in Sca-1 + fibroblasts (Figure 14).
이는 본 발명의 244-cis LNP가 MC3 LNP와 비교하여 mRNA를 폐 특이적으로 전달하여 발현시킬 수 있고, 특히 폐 섬유화증 모델에서 섬유아세포에 mRNA를 표적 전달할 수 있다는 것을 시사한다.This suggests that the 244-cis LNP of the present invention can deliver and express mRNA specifically to the lung compared to the MC3 LNP, and can specifically deliver mRNA to fibroblasts in a lung fibrosis model.
이상의 설명으로부터, 본 발명의 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art will understand that the present invention can be implemented in other specific forms without changing its technical idea or essential features. In this regard, the embodiments described above should be understood in all respects as illustrative and not restrictive. The scope of the present invention should be construed as including the meaning and scope of the patent claims described below rather than the detailed description above, and all changes or modified forms derived from the equivalent concept thereof are included in the scope of the present invention.
Claims (12)
- 하기 화학식 1의 이온화 가능 지질 및 양이온성 지질을 포함하는 지질나노입자를 포함하는, 약물의 경폐 전달용 조성물:A composition for transpulmonary delivery of a drug, comprising lipid nanoparticles containing an ionizable lipid and a cationic lipid of the following formula (1):[화학식 1][Formula 1].
. - 제1항에 있어서, 상기 양이온성 지질은 DOTAP (1,2-dioleoyl-3-trimethylammonium propane) 또는 포스파티딜콜린 (phosphatidylcholine)인, 약물의 경폐 전달용 조성물.The composition for transpulmonary delivery of a drug according to claim 1, wherein the cationic lipid is DOTAP (1,2-dioleoyl-3-trimethylammonium propane) or phosphatidylcholine.
- 제1항에 있어서, 상기 지질나노입자는 구조적 지질 또는 PEG-지질을 더 포함하는, 약물의 경폐 전달용 조성물.The composition for transpulmonary delivery of a drug according to claim 1, wherein the lipid nanoparticles further include structural lipids or PEG-lipids.
- 제3항에 있어서, 상기 구조적 지질은 콜레스테롤, 콜레스테놀, 스피나스테롤, 페코스테롤, 시토스테롤, 에르고스테롤, 에르고스테놀, 캄페스테롤, 스티그마스테롤, 브라시카스테롤, 토마티딘, 우르솔산 및 알파-토코페롤로 이루어진 군에서 선택되는 어느 하나 이상인, 약물의 경폐 전달용 조성물.4. The method of claim 3, wherein the structural lipids are cholesterol, cholesterol, spinasterol, fecosterol, sitosterol, ergosterol, ergostenol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid and alpha - A composition for transpulmonary delivery of a drug, which is at least one selected from the group consisting of tocopherol.
- 제3항에 있어서, 상기 PEG-지질은 PEG-세라마이드, PEG-DMG, PEG-c-DOMG, PEG-DLPE, PEG-DMPE, PEG-DPPC 및 PEG-DSPE로 이루어진 군으로부터 선택되는 어느 하나 이상인, 약물의 경폐 전달용 조성물.The method of claim 3, wherein the PEG-lipid is at least one selected from the group consisting of PEG-ceramide, PEG-DMG, PEG-c-DOMG, PEG-DLPE, PEG-DMPE, PEG-DPPC and PEG-DSPE. Composition for transpulmonary delivery of drugs.
- 제3항에 있어서, 상기 DOTAP은 지질나노입자 전체를 기준으로 10 mol% 내지 70 mol%로 포함되는 것인, 약물의 경폐 전달용 조성물.The composition for transpulmonary delivery of a drug according to claim 3, wherein the DOTAP is contained in an amount of 10 mol% to 70 mol% based on the total lipid nanoparticles.
- 제3항에 있어서, 상기 포스파티딜콜린은 지질나노입자 전체를 기준으로 10 mol% 내지 50 mol%로 포함되는 것인, 약물의 경폐 전달용 조성물.The composition for transpulmonary delivery of a drug according to claim 3, wherein the phosphatidylcholine is contained in an amount of 10 mol% to 50 mol% based on the total lipid nanoparticles.
- i) 하기 화학식 1의 이온화 가능 지질 및 양이온성 지질을 포함하는 지질나노입자, 및 ii) 음이온성 약물을 유효성분으로 포함하는, 폐 질환의 예방 또는 치료용 약학적 조성물:i) Lipid nanoparticles containing an ionizable lipid and a cationic lipid of the following formula (1), and ii) a pharmaceutical composition for the prevention or treatment of lung disease, containing an anionic drug as an active ingredient:[화학식 1][Formula 1].
. - 제8항에 있어서, 상기 양이온성 지질은 DOTAP (1,2-dioleoyl-3-trimethylammonium propane) 또는 포스파티딜콜린 (phosphatidylcholine)인, 폐 질환의 예방 또는 치료용 약학적 조성물.The pharmaceutical composition for preventing or treating lung disease according to claim 8, wherein the cationic lipid is DOTAP (1,2-dioleoyl-3-trimethylammonium propane) or phosphatidylcholine.
- 제8항에 있어서, 상기 음이온성 약물은 핵산 약물인, 폐 질환의 예방 또는 치료용 약학적 조성물.The pharmaceutical composition for preventing or treating lung disease according to claim 8, wherein the anionic drug is a nucleic acid drug.
- 제10항에 있어서, 상기 핵산 약물은 소간섭 리보핵산 (siRNA), 리보좀 리보핵산 (rRNA), 디옥시리보핵산 (DNA), 상보성 디옥시리보핵산 (cDNA), 앱타머 (aptamer), 전령 리보핵산 (mRNA), 운반 리보핵산 (tRNA), sgRNA, 안티센스 올리고뉴클레오티드, shRNA, miRNA, 리보자임 (ribozyme), PNA, 및 DNAzyme로 이루어진 군에서 선택되는 어느 하나 이상인, 폐 질환의 예방 또는 치료용 약학적 조성물.11. The method of claim 10, wherein the nucleic acid drug is small interfering ribonucleic acid (siRNA), ribosomal ribonucleic acid (rRNA), deoxyribonucleic acid (DNA), complementary deoxyribonucleic acid (cDNA), aptamer, messenger ribonucleic acid (mRNA). , a pharmaceutical composition for preventing or treating lung disease, which is at least one selected from the group consisting of transport ribonucleic acid (tRNA), sgRNA, antisense oligonucleotide, shRNA, miRNA, ribozyme, PNA, and DNAzyme.
- 제8항에 있어서, 상기 폐질환은 폐기종, 천식, 폐렴, 결핵, 폐 고혈압, 폐암, 신생아 기관지폐 형성 장애증, 만성 폐쇄성 폐질환, 급성 기관지염, 만성 기관지염, 세기관지염, 기관지 확장증, 과민증, 폐실질 염, 급성 연기 흡입, 열에 의한 폐 손상, 낭포성 섬유증, 허파꽈리 단백증, 알파-1-프로테아제 결핍, 폐 염증성 장애, 급성 호흡 곤란 증후군, 급성 폐 손상, 특발성 호흡 곤란 증후군 및 폐 섬유증으로 이루어진 군에서 선택된 1종 이상인, 폐 질환의 예방 또는 치료용 약학적 조성물.The method of claim 8, wherein the lung disease includes emphysema, asthma, pneumonia, tuberculosis, pulmonary hypertension, lung cancer, neonatal bronchopulmonary dysplasia, chronic obstructive pulmonary disease, acute bronchitis, chronic bronchitis, bronchiolitis, bronchiectasis, hypersensitivity, lung parenchyma. A group consisting of salts, acute smoke inhalation, heat-induced lung injury, cystic fibrosis, alveolar proteinosis, alpha-1-protease deficiency, pulmonary inflammatory disorders, acute respiratory distress syndrome, acute lung injury, idiopathic respiratory distress syndrome, and pulmonary fibrosis. A pharmaceutical composition for preventing or treating lung disease, which is one or more types selected from.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20220140249 | 2022-10-27 | ||
| KR10-2022-0140249 | 2022-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024091037A1 true WO2024091037A1 (en) | 2024-05-02 |
Family
ID=90831413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2023/016792 WO2024091037A1 (en) | 2022-10-27 | 2023-10-26 | Biodegradable lipid nanoparticle drug delivery formulation targeting lungs |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20240083166A (en) |
| WO (1) | WO2024091037A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140308304A1 (en) * | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| US20150166462A1 (en) * | 2012-03-29 | 2015-06-18 | Shire Human Genetic Therapies. Inc. | Ionizable cationic lipids |
| KR20190093816A (en) * | 2016-10-26 | 2019-08-26 | 큐어백 아게 | Lipid nanoparticle mRNA vaccine |
| US20210107861A1 (en) * | 2014-06-25 | 2021-04-15 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| WO2023136689A1 (en) * | 2022-01-17 | 2023-07-20 | 에스티팜 주식회사 | Ionizable lipid containing biodegradable ester bond and lipid nanoparticles comprising same |
-
2023
- 2023-10-26 KR KR1020230145077A patent/KR20240083166A/en unknown
- 2023-10-26 WO PCT/KR2023/016792 patent/WO2024091037A1/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140308304A1 (en) * | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| US20150166462A1 (en) * | 2012-03-29 | 2015-06-18 | Shire Human Genetic Therapies. Inc. | Ionizable cationic lipids |
| US20210107861A1 (en) * | 2014-06-25 | 2021-04-15 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| KR20190093816A (en) * | 2016-10-26 | 2019-08-26 | 큐어백 아게 | Lipid nanoparticle mRNA vaccine |
| WO2023136689A1 (en) * | 2022-01-17 | 2023-07-20 | 에스티팜 주식회사 | Ionizable lipid containing biodegradable ester bond and lipid nanoparticles comprising same |
Non-Patent Citations (1)
| Title |
|---|
| KEJIN ZHOU: "Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 113, no. 3, 19 January 2016 (2016-01-19), pages 520 - 525, XP093163988, ISSN: 0027-8424, DOI: 10.1073/pnas.1520756113 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240083166A (en) | 2024-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Antimisiaris et al. | Overcoming barriers by local drug delivery with liposomes | |
| KR102198736B1 (en) | Lipid nanoparticles for in vivo drug delivery and uses thereof | |
| EP2567693B1 (en) | Lipid encapsulated interfering RNA | |
| EP2430168B1 (en) | Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules | |
| KR101476167B1 (en) | Transpulmonary liposome for controlling drug arrival | |
| JP2012509258A (en) | Branched cationic lipids for nucleic acid delivery systems | |
| WO2013070010A1 (en) | Novel composition for gene delivery | |
| CN104582691A (en) | Lipid-coated albumin nanoparticle compositions and methods of making and method of using the same | |
| KR20010101752A (en) | Transnasal transport/immunisation with highly adaptable carriers | |
| JP2012509366A (en) | Releasable polymeric lipids for nucleic acid delivery systems | |
| JP5382682B2 (en) | Drug delivery complex | |
| WO2019212288A1 (en) | Polymer nanoparticle composition for delivering messenger rna, and preparation method therefor | |
| KR20130062953A (en) | Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same | |
| JP3804452B2 (en) | Hepatitis treatment agent | |
| WO2023136689A1 (en) | Ionizable lipid containing biodegradable ester bond and lipid nanoparticles comprising same | |
| WO2024091037A1 (en) | Biodegradable lipid nanoparticle drug delivery formulation targeting lungs | |
| WO2024010330A1 (en) | Lipid nanoparticles using cationic cholesterol for local delivery for nucleic acid delivery | |
| KR20240082389A (en) | Ionizable lipids containing biodegradable disulfide bonds and lipid nanoparticles containing them | |
| EP1029544A1 (en) | Intra-cancer-cell nuclease activator | |
| WO2024096516A1 (en) | Lipid nanoparticle formulation for transpulmonary delivery of nucleic acid drugs and use thereof | |
| Betker et al. | Nonadditive effects of repetitive administration of lipoplexes in immunocompetent mice | |
| WO2024177282A1 (en) | Ionizable lipid comprising sulfide, and lipid nanoparticles comprising same | |
| WO2024177426A1 (en) | Lipid nanoparicles for in vivo drug delivery | |
| WO2023190176A1 (en) | Lipid nanoparticles for delivering nucleic acid to splenic tissue, and method for delivering nucleic acid to splenic tissue using same | |
| EP4410275A1 (en) | Lipid nanoparticle used for delivering nucleic acid to brain tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23883142 Country of ref document: EP Kind code of ref document: A1 |